<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7370876\results\search\disease\results.xml">
  <result pre="UKLondon pmcid: 7370876413 doi: 10.1038/s41569-020-0413-9 : Review Article COVID-19 and" exact="cardiovascular" post="disease: from basic mechanisms to clinical perspectives http://orcid.org/0000-0001-5676-7671NishigaMasatakamnishiga@stanford.edu12WangDao Wen3HanYaling4LewisDavid"/>
  <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
  <result pre="(WHO) declaration of COVID-19 as a global pandemic. Abstract Coronavirus" exact="disease" post="2019 (COVID-19), caused by a strain of coronavirus known"/>
  <result pre="(COVID-19), caused by a strain of coronavirus known as severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global"/>
  <result pre="caused by a strain of coronavirus known as severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic"/>
  <result pre="by a strain of coronavirus known as severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), has become a global pandemic that"/>
  <result pre="the zoonotic virus that caused the 2002 outbreak of severe" exact="acute" post="respiratory syndrome, including the system of cell entry, which"/>
  <result pre="zoonotic virus that caused the 2002 outbreak of severe acute" exact="respiratory" post="syndrome, including the system of cell entry, which is"/>
  <result pre="of cell entry, which is triggered by binding of the" exact="viral" post="spike protein to angiotensin-converting enzyme 2. Clinical studies have"/>
  <result pre="Clinical studies have also reported an association between COVID-19 and" exact="cardiovascular disease." post="Pre-existing cardiovascular disease seems to be linked with worse"/>
  <result pre="also reported an association between COVID-19 and cardiovascular disease. Pre-existing" exact="cardiovascular disease" post="seems to be linked with worse outcomes and increased"/>
  <result pre="reported an association between COVID-19 and cardiovascular disease. Pre-existing cardiovascular" exact="disease" post="seems to be linked with worse outcomes and increased"/>
  <result pre="COVID-19, whereas COVID-19 itself can also induce myocardial injury, arrhythmia," exact="acute" post="coronary syndrome and venous thromboembolism. Potential drugâ€&quot;disease interactions affecting"/>
  <result pre="COVID-19 itself can also induce myocardial injury, arrhythmia, acute coronary" exact="syndrome" post="and venous thromboembolism. Potential drugâ€&quot;disease interactions affecting patients with"/>
  <result pre="can also induce myocardial injury, arrhythmia, acute coronary syndrome and" exact="venous thromboembolism." post="Potential drugâ€&quot;disease interactions affecting patients with COVID-19 and comorbid"/>
  <result pre="thromboembolism. Potential drugâ€&quot;disease interactions affecting patients with COVID-19 and comorbid" exact="cardiovascular" post="diseases are also becoming a serious concern. In this"/>
  <result pre="clinical perspectives, focusing on the interaction between COVID-19 and the" exact="cardiovascular" post="system. By combining our knowledge of the biological features"/>
  <result pre="the development of preventative and therapeutic solutions. The presence of" exact="cardiovascular" post="comorbidities is linked with worse outcomes in patients with"/>
  <result pre="comorbidities is linked with worse outcomes in patients with coronavirus" exact="disease" post="2019 (COVID-19), and COVID-19 can induce cardiovascular damage. In"/>
  <result pre="patients with coronavirus disease 2019 (COVID-19), and COVID-19 can induce" exact="cardiovascular" post="damage. In this Review, Wu and colleagues summarize the"/>
  <result pre="clinical studies that contribute to our current understanding of COVID-19-related" exact="cardiovascular disease." post="Key points Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),"/>
  <result pre="to our current understanding of COVID-19-related cardiovascular disease. Key points" exact="Severe" post="acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that"/>
  <result pre="our current understanding of COVID-19-related cardiovascular disease. Key points Severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes"/>
  <result pre="current understanding of COVID-19-related cardiovascular disease. Key points Severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus"/>
  <result pre="understanding of COVID-19-related cardiovascular disease. Key points Severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease"/>
  <result pre="respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus" exact="disease" post="2019 (COVID-19), shares many biological features with SARS-CoV, the"/>
  <result pre="many biological features with SARS-CoV, the virus that causes severe" exact="acute" post="respiratory syndrome, owing to 80% genomic sequence identity. The"/>
  <result pre="biological features with SARS-CoV, the virus that causes severe acute" exact="respiratory" post="syndrome, owing to 80% genomic sequence identity. The interaction"/>
  <result pre="owing to 80% genomic sequence identity. The interaction between the" exact="viral" post="spike (S) protein and angiotensin-converting enzyme 2, which triggers"/>
  <result pre="into host cells, is likely to be involved in the" exact="cardiovascular" post="manifestations of COVID-19. The presence of underlying cardiovascular comorbidities"/>
  <result pre="in the cardiovascular manifestations of COVID-19. The presence of underlying" exact="cardiovascular" post="comorbidities in patients with COVID-19 is associated with high"/>
  <result pre="with COVID-19 is associated with high mortality. COVID-19 can cause" exact="cardiovascular" post="disorders, including myocardial injury, arrhythmias, acute coronary syndrome and"/>
  <result pre="mortality. COVID-19 can cause cardiovascular disorders, including myocardial injury, arrhythmias," exact="acute" post="coronary syndrome and venous thromboembolism. Several medications used for"/>
  <result pre="can cause cardiovascular disorders, including myocardial injury, arrhythmias, acute coronary" exact="syndrome" post="and venous thromboembolism. Several medications used for the treatment"/>
  <result pre="cardiovascular disorders, including myocardial injury, arrhythmias, acute coronary syndrome and" exact="venous thromboembolism." post="Several medications used for the treatment of COVID-19 have"/>
  <result pre="profiles. Subject terms Cardiovascular diseases SARS-CoV-2 Molecular biology Introduction Coronavirus" exact="disease" post="2019 (COVID-19) was first reported in Wuhan, China, in"/>
  <result pre="for COVID-19 are not available. COVID-19 is caused by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), which is a member"/>
  <result pre="COVID-19 are not available. COVID-19 is caused by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), which is a member of"/>
  <result pre="are not available. COVID-19 is caused by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), which is a member of the"/>
  <result pre="the two other coronaviruses that have caused pandemic diseases (severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome"/>
  <result pre="two other coronaviruses that have caused pandemic diseases (severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus"/>
  <result pre="other coronaviruses that have caused pandemic diseases (severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV))1â€&quot;4."/>
  <result pre="diseases (severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV))1â€&quot;4. As with SARS-CoV and MERS-CoV, SARS-CoV-2"/>
  <result pre="(severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV))1â€&quot;4. As with SARS-CoV and MERS-CoV, SARS-CoV-2 causes"/>
  <result pre="coronavirus (MERS-CoV))1â€&quot;4. As with SARS-CoV and MERS-CoV, SARS-CoV-2 causes a" exact="respiratory" post="infection, which leads to viral pneumonia and acute respiratory"/>
  <result pre="and MERS-CoV, SARS-CoV-2 causes a respiratory infection, which leads to" exact="viral pneumonia" post="and acute respiratory distress syndrome (ARDS) in some patients1."/>
  <result pre="MERS-CoV, SARS-CoV-2 causes a respiratory infection, which leads to viral" exact="pneumonia" post="and acute respiratory distress syndrome (ARDS) in some patients1."/>
  <result pre="causes a respiratory infection, which leads to viral pneumonia and" exact="acute" post="respiratory distress syndrome (ARDS) in some patients1. However, in"/>
  <result pre="a respiratory infection, which leads to viral pneumonia and acute" exact="respiratory" post="distress syndrome (ARDS) in some patients1. However, in addition"/>
  <result pre="infection, which leads to viral pneumonia and acute respiratory distress" exact="syndrome" post="(ARDS) in some patients1. However, in addition to respiratory"/>
  <result pre="distress syndrome (ARDS) in some patients1. However, in addition to" exact="respiratory" post="symptoms, uncontrolled SARS-CoV-2 infection can trigger a cytokine storm,"/>
  <result pre="(ARDS) in some patients1. However, in addition to respiratory symptoms," exact="uncontrolled" post="SARS-CoV-2 infection can trigger a cytokine storm, whereby pro-inflammatory"/>
  <result pre="some patients1. However, in addition to respiratory symptoms, uncontrolled SARS-CoV-2" exact="infection" post="can trigger a cytokine storm, whereby pro-inflammatory cytokines and"/>
  <result pre="which can lead to thromboembolic events6,7. The genomic sequence1â€&quot;3,8 and" exact="viral" post="protein structure9â€&quot;11 of SARS-CoV-2 have been studied intensively since"/>
  <result pre="of cell entry, which is triggered by binding of the" exact="viral" post="spike (S) protein to angiotensin-converting enzyme 2 (ACE2) on"/>
  <result pre="of tissue tropism. Early clinical data indicate that both the" exact="susceptibility to" post="and the outcomes of COVID-19 are strongly associated with"/>
  <result pre="to and the outcomes of COVID-19 are strongly associated with" exact="cardiovascular disease" post="(CVD)12â€&quot;16. A high prevalence of pre-existing CVD has been"/>
  <result pre="and the outcomes of COVID-19 are strongly associated with cardiovascular" exact="disease" post="(CVD)12â€&quot;16. A high prevalence of pre-existing CVD has been"/>
  <result pre="increased mortality17â€&quot;22. Furthermore, COVID-19 seems to promote the development of" exact="cardiovascular" post="disorders, such as myocardial injury, arrhythmias, acute coronary syndrome"/>
  <result pre="the development of cardiovascular disorders, such as myocardial injury, arrhythmias," exact="acute" post="coronary syndrome (ACS) and venous thromboembolism23â€&quot;25. Children with COVID-19"/>
  <result pre="of cardiovascular disorders, such as myocardial injury, arrhythmias, acute coronary" exact="syndrome" post="(ACS) and venous thromboembolism23â€&quot;25. Children with COVID-19 have also"/>
  <result pre="been reported to develop hyperinflammatory shock with features akin to" exact="Kawasaki disease," post="including cardiac dysfunction and coronary vessel abnormalities26. Together, these"/>
  <result pre="the presence of a bidirectional interaction between COVID-19 and the" exact="cardiovascular" post="system, but the mechanisms underlying this interaction remain elusive."/>
  <result pre="mechanisms underlying this interaction remain elusive. The high burden of" exact="systemic" post="inflammation associated with COVID-19 has been proposed to accelerate"/>
  <result pre="accelerate the development of subclinical disorders or cause de novo" exact="cardiovascular" post="damage5,12â€&quot;14. ACE2, which is a key surface protein for"/>
  <result pre="COVID-19 to improve our understanding of the pathophysiology of the" exact="disease" post="and to contribute to the development of potential therapies."/>
  <result pre="biological viewpoint, with an emphasis on the interaction between the" exact="viral" post="S protein and human ACE2. Furthermore, we provide an"/>
  <result pre="clinical findings related to the effects of COVID-19 on the" exact="cardiovascular" post="system. Finally, we discuss the possible link between common"/>
  <result pre="cardiovascular system. Finally, we discuss the possible link between common" exact="cardiovascular" post="drugs and susceptibility to COVID-19 and the potential cardiovascular"/>
  <result pre="we discuss the possible link between common cardiovascular drugs and" exact="susceptibility to" post="COVID-19 and the potential cardiovascular effects of drugs used"/>
  <result pre="common cardiovascular drugs and susceptibility to COVID-19 and the potential" exact="cardiovascular" post="effects of drugs used to treat COVID-19. Of note,"/>
  <result pre="novel coronavirus through genomic sequence studies1â€&quot;3 and the evaluation of" exact="viral" post="protein structure9â€&quot;11,27,28. Coronaviruses, which are a large family of"/>
  <result pre="(E), membrane (M) and nucleocapsid (N) proteins29,30,32 (Fig.Â 1a). The" exact="viral" post="genome surrounded by the N protein is a positive-sense,"/>
  <result pre="in length. b | The 5â€²-terminal two-thirds of the severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) genome encodes polyproteins pp1a"/>
  <result pre="length. b | The 5â€²-terminal two-thirds of the severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) genome encodes polyproteins pp1a and"/>
  <result pre="b | The 5â€²-terminal two-thirds of the severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) genome encodes polyproteins pp1a and pp1ab,"/>
  <result pre="and pp1ab, which are cleaved into 16 different non-structural proteins." exact="Structural" post="proteins are encoded in the 3â€²-terminal one-third of the"/>
  <result pre="which introduces a novel furin cleavage site. c | SARS-CoV-2" exact="infection" post="is triggered by the binding of the S protein"/>
  <result pre="to ACE2 on the surface of host cells, and the" exact="viral" post="complex is incorporated into the cytoplasm either by direct"/>
  <result pre="S1/S2 boundary and the S2 subunit facilitates membrane fusion. The" exact="viral" post="genome RNA is released into the cytoplasm, and the"/>
  <result pre="into polyproteins pp1a and pp1ab, which are then cleaved by" exact="viral" post="proteases into small, non-structural proteins such as RNA-dependent RNA"/>
  <result pre="small, non-structural proteins such as RNA-dependent RNA polymerase (RdRP). The" exact="viral" post="genomic RNA is replicated by RdRP. Viral nucleocapsids are"/>
  <result pre="polymerase (RdRP). The viral genomic RNA is replicated by RdRP." exact="Viral" post="nucleocapsids are assembled from genomic RNA and N proteins"/>
  <result pre="the genomic RNA and structural proteins are assembled into new" exact="viral" post="particles, leading to their release via exocytosis. 3CL, 3-chymotrypsin-like"/>
  <result pre="protein has pivotal roles in virus attachment and entry and" exact="disease" post="pathogenesis9â€&quot;11,29,30. In SARS-CoV and SARS-CoV-2, the binding of the"/>
  <result pre="disease pathogenesis9â€&quot;11,29,30. In SARS-CoV and SARS-CoV-2, the binding of the" exact="viral" post="S protein to ACE2 triggers virus entry into the"/>
  <result pre="unknown, similar cleavage sites have been described in highly pathogenic" exact="avian influenza" post="viruses and the Newcastle disease virus4,8. This notable feature"/>
  <result pre="been described in highly pathogenic avian influenza viruses and the" exact="Newcastle disease" post="virus4,8. This notable feature has been proposed to have"/>
  <result pre="described in highly pathogenic avian influenza viruses and the Newcastle" exact="disease" post="virus4,8. This notable feature has been proposed to have"/>
  <result pre="effects of COVID-19 (Fig.Â 1b). Life cycle of the virus" exact="Infection" post="with either SARS-CoV or SARS-CoV-2 involves binding of the"/>
  <result pre="Infection with either SARS-CoV or SARS-CoV-2 involves binding of the" exact="viral" post="S protein to ACE2 on the surface of the"/>
  <result pre="protease TMPRSS2, which in turn facilitates the fusion of the" exact="viral" post="membrane with the membrane of the host cell and"/>
  <result pre="direct entry of the virus into the cytoplasm4,29,30,40 (Fig.Â 1c)." exact="Respiratory" post="tract epithelial cells express both ACE2 and TMPRSS2 on"/>
  <result pre="of the virus into the cytoplasm4,29,30,40 (Fig.Â 1c). Respiratory tract" exact="epithelial" post="cells express both ACE2 and TMPRSS2 on their surface,"/>
  <result pre="in vivo entry by SARS-CoV and, probably, SARS-CoV-2 into the" exact="respiratory" post="tissue40. Alternatively, SARS-CoV-2 can also use an endosomal entry"/>
  <result pre="be the predominant entry pathway used by coronaviruses in the" exact="infection" post="of cells cultured in vitro40, but the importance of"/>
  <result pre="cultured in vitro40, but the importance of this pathway for" exact="infection" post="in vivo remains unclear. After the release of the"/>
  <result pre="infection in vivo remains unclear. After the release of the" exact="viral" post="genomic RNA into the cytoplasm, the first ORF is"/>
  <result pre="into polyproteins pp1a and pp1ab, which are then cleaved by" exact="viral" post="proteases into small non-structural proteins such as RdRP. The"/>
  <result pre="viral proteases into small non-structural proteins such as RdRP. The" exact="viral" post="genomic RNA is then replicated using viral RdRP, and"/>
  <result pre="as RdRP. The viral genomic RNA is then replicated using" exact="viral" post="RdRP, and the four structural proteins (S, E, M"/>
  <result pre="the genomic RNA and structural proteins are assembled into new" exact="viral" post="particles, leading to their release through exocytosis29,30 (Fig.Â 1c)."/>
  <result pre="their release through exocytosis29,30 (Fig.Â 1c). Each step of the" exact="viral" post="life cycle described here is a potential therapeutic target,"/>
  <result pre="target of the antiviral agents favipiravir, remdesivir and ribavirin)41,42. The" exact="cardiovascular" post="system and COVID-19 Underlying cardiovascular comorbidities CVD is a"/>
  <result pre="favipiravir, remdesivir and ribavirin)41,42. The cardiovascular system and COVID-19 Underlying" exact="cardiovascular" post="comorbidities CVD is a common comorbidity observed in patients"/>
  <result pre="China found that CVD and its risk factors, such as" exact="hypertension" post="and diabetes mellitus, were common pre-existing conditions in patients"/>
  <result pre="that CVD and its risk factors, such as hypertension and" exact="diabetes mellitus," post="were common pre-existing conditions in patients with COVID-19, but"/>
  <result pre="comorbidity was 32% and the most common underlying diseases were" exact="diabetes" post="(20%), hypertension (15%) and other CVDs (15%)17. The high"/>
  <result pre="32% and the most common underlying diseases were diabetes (20%)," exact="hypertension" post="(15%) and other CVDs (15%)17. The high prevalence of"/>
  <result pre="(72% of patients in the ICU), 31% of patients had" exact="hypertension" post="(58% of patients in the ICU), 15% of patients"/>
  <result pre="of patients in the ICU) and 10% of patients had" exact="diabetes" post="(22% of patients in the ICU)18. Similarly, in a"/>
  <result pre="comorbidity (67% of those who died), 30% of patients had" exact="hypertension" post="(48% of those who died), 19% of patients had"/>
  <result pre="hypertension (48% of those who died), 19% of patients had" exact="diabetes" post="(31% of those who died) and 8% of patients"/>
  <result pre="(31% of those who died) and 8% of patients had" exact="coronary heart disease" post="(24% of those who died)19. Furthermore, in a report"/>
  <result pre="of those who died) and 8% of patients had coronary" exact="heart" post="disease (24% of those who died)19. Furthermore, in a"/>
  <result pre="those who died) and 8% of patients had coronary heart" exact="disease" post="(24% of those who died)19. Furthermore, in a report"/>
  <result pre="comorbidity (39% of critically ill patients), 15% of patients had" exact="hypertension" post="(24% of critically ill patients), 7% of patients had"/>
  <result pre="hypertension (24% of critically ill patients), 7% of patients had" exact="diabetes" post="(16% of critically ill patients) and 3% of patients"/>
  <result pre="(16% of critically ill patients) and 3% of patients had" exact="coronary heart disease" post="(6% of critically ill patients)20. The overall case fatality"/>
  <result pre="of critically ill patients) and 3% of patients had coronary" exact="heart" post="disease (6% of critically ill patients)20. The overall case"/>
  <result pre="critically ill patients) and 3% of patients had coronary heart" exact="disease" post="(6% of critically ill patients)20. The overall case fatality"/>
  <result pre="fatality rate of COVID-19 reported by the Chinese Center for" exact="Disease" post="Control and Prevention as of 11 February 2020 was"/>
  <result pre="CVD was 10.5% (highest among those with any comorbidities, including" exact="chronic" post="respiratory disease (6.3%) or cancer (5.6%)), the case fatality"/>
  <result pre="was 10.5% (highest among those with any comorbidities, including chronic" exact="respiratory" post="disease (6.3%) or cancer (5.6%)), the case fatality rate"/>
  <result pre="10.5% (highest among those with any comorbidities, including chronic respiratory" exact="disease" post="(6.3%) or cancer (5.6%)), the case fatality rate of"/>
  <result pre="those with any comorbidities, including chronic respiratory disease (6.3%) or" exact="cancer" post="(5.6%)), the case fatality rate of patients with diabetes"/>
  <result pre="or cancer (5.6%)), the case fatality rate of patients with" exact="diabetes" post="was 7.3% and that of patients with hypertension was"/>
  <result pre="patients with diabetes was 7.3% and that of patients with" exact="hypertension" post="was 6.0%45. Of note, these early approximations of case"/>
  <result pre="the virus but were not tested. Table 1 Prevalence of" exact="cardiovascular" post="comorbidities in patients with COVID-19 Country Number of patients"/>
  <result pre="(among patients who were ventilated or in ICU) Ref. Cardiovascular" exact="disease" post="(%) Hypertension (%) Diabetes (%) Obesity (%) China 41"/>
  <result pre="who were ventilated or in ICU) Ref. Cardiovascular disease (%)" exact="Hypertension" post="(%) Diabetes (%) Obesity (%) China 41 15 (23)"/>
  <result pre="ventilated or in ICU) Ref. Cardiovascular disease (%) Hypertension (%)" exact="Diabetes" post="(%) Obesity (%) China 41 15 (23) 15 (15)"/>
  <result pre="in ICU) Ref. Cardiovascular disease (%) Hypertension (%) Diabetes (%)" exact="Obesity" post="(%) China 41 15 (23) 15 (15) 20 (8)"/>
  <result pre="among critically ill patients is shown in parentheses. aPrevalence of" exact="coronary artery disease" post="specifically. bPrevalence of comorbidity among patients who died. COVID-19,"/>
  <result pre="critically ill patients is shown in parentheses. aPrevalence of coronary" exact="artery disease" post="specifically. bPrevalence of comorbidity among patients who died. COVID-19,"/>
  <result pre="ill patients is shown in parentheses. aPrevalence of coronary artery" exact="disease" post="specifically. bPrevalence of comorbidity among patients who died. COVID-19,"/>
  <result pre="specifically. bPrevalence of comorbidity among patients who died. COVID-19, coronavirus" exact="disease" post="2019; ICU, intensive care unit; NR, not reported. A"/>
  <result pre="in New York, USA, up to 50% of patients had" exact="hypertension" post="(54% of ventilated patients), 36% had obesity (43% of"/>
  <result pre="of patients had hypertension (54% of ventilated patients), 36% had" exact="obesity" post="(43% of ventilatedÂ patients), 25% of patients had diabetes"/>
  <result pre="had obesity (43% of ventilatedÂ patients), 25% of patients had" exact="diabetes" post="(28% of ventilated patients) and 14% of patients had"/>
  <result pre="diabetes (28% of ventilated patients) and 14% of patients had" exact="coronary artery disease" post="(19% of ventilated patients)47. Of note, this study from"/>
  <result pre="(28% of ventilated patients) and 14% of patients had coronary" exact="artery disease" post="(19% of ventilated patients)47. Of note, this study from"/>
  <result pre="of ventilated patients) and 14% of patients had coronary artery" exact="disease" post="(19% of ventilated patients)47. Of note, this study from"/>
  <result pre="study from New York highlighted the high prevalence of comorbid" exact="obesity" post="among patients with COVID-19, which had not been reported"/>
  <result pre="China probably owing to differences in the background prevalence of" exact="obesity" post="between the USA and China. Investigators in this study"/>
  <result pre="the USA and China. Investigators in this study suggest that" exact="obesity" post="might also be a risk factor for respiratory failure"/>
  <result pre="suggest that obesity might also be a risk factor for" exact="respiratory" post="failure and the need for invasive mechanical ventilation47. Diverse"/>
  <result pre="respiratory failure and the need for invasive mechanical ventilation47. Diverse" exact="cardiovascular" post="manifestations Although the predominant clinical manifestation of COVID-19 is"/>
  <result pre="cardiovascular manifestations Although the predominant clinical manifestation of COVID-19 is" exact="viral" post="pneumonia1,2,48,49, COVID-19 can also cause cardiovascular disorders such as"/>
  <result pre="manifestation of COVID-19 is viral pneumonia1,2,48,49, COVID-19 can also cause" exact="cardiovascular" post="disorders such as myocardial injury, arrhythmias, ACS and thromboembolism12â€&quot;15"/>
  <result pre="Furthermore, a possible link between COVID-19 and a Kawasaki disease-like" exact="syndrome" post="has been described in children26. Fig. 2 Bidirectional interaction"/>
  <result pre="has been described in children26. Fig. 2 Bidirectional interaction between" exact="cardiovascular" post="diseases and COVID-19. Cardiovascular comorbidities such as hypertension and"/>
  <result pre="interaction between cardiovascular diseases and COVID-19. Cardiovascular comorbidities such as" exact="hypertension" post="and coronary artery disease are associated with high mortality"/>
  <result pre="cardiovascular diseases and COVID-19. Cardiovascular comorbidities such as hypertension and" exact="coronary artery disease" post="are associated with high mortality in patients with coronavirus"/>
  <result pre="diseases and COVID-19. Cardiovascular comorbidities such as hypertension and coronary" exact="artery disease" post="are associated with high mortality in patients with coronavirus"/>
  <result pre="and COVID-19. Cardiovascular comorbidities such as hypertension and coronary artery" exact="disease" post="are associated with high mortality in patients with coronavirus"/>
  <result pre="disease are associated with high mortality in patients with coronavirus" exact="disease" post="2019 (COVID-19). Drugs used to reduce cardiovascular risk such"/>
  <result pre="patients with coronavirus disease 2019 (COVID-19). Drugs used to reduce" exact="cardiovascular" post="risk such as angiotensin-converting enzyme (ACE) inhibitors and angiotensin"/>
  <result pre="II receptor blockers (ARBs) have numerous effects that might influence" exact="susceptibility to" post="or the severity of COVID-19. Furthermore, although the main"/>
  <result pre="of COVID-19. Furthermore, although the main presentation of COVID-19 is" exact="viral pneumonia," post="COVID-19 can also induce cardiovascular manifestations including myocardial injury,"/>
  <result pre="presentation of COVID-19 is viral pneumonia, COVID-19 can also induce" exact="cardiovascular" post="manifestations including myocardial injury, myocarditis, arrhythmias, acute coronary syndrome"/>
  <result pre="can also induce cardiovascular manifestations including myocardial injury, myocarditis, arrhythmias," exact="acute" post="coronary syndrome and thromboembolism. Among these cardiovascular manifestations, myocardial"/>
  <result pre="induce cardiovascular manifestations including myocardial injury, myocarditis, arrhythmias, acute coronary" exact="syndrome" post="and thromboembolism. Among these cardiovascular manifestations, myocardial injury has"/>
  <result pre="injury, myocarditis, arrhythmias, acute coronary syndrome and thromboembolism. Among these" exact="cardiovascular" post="manifestations, myocardial injury has been independently associated with high"/>
  <result pre="COVID-19 such as hydroxychloroquine and azithromycin have pro-arrhythmic effects. AF," exact="atrial fibrillation;" post="VF, ventricular fibrillation; VT, ventricular tachycardia. Myocardial injury and"/>
  <result pre="hydroxychloroquine and azithromycin have pro-arrhythmic effects. AF, atrial fibrillation; VF," exact="ventricular fibrillation;" post="VT, ventricular tachycardia. Myocardial injury and myocarditis Acute myocardial"/>
  <result pre="have pro-arrhythmic effects. AF, atrial fibrillation; VF, ventricular fibrillation; VT," exact="ventricular tachycardia." post="Myocardial injury and myocarditis Acute myocardial injury, as evidenced"/>
  <result pre="fibrillation; VF, ventricular fibrillation; VT, ventricular tachycardia. Myocardial injury and" exact="myocarditis" post="Acute myocardial injury, as evidenced by elevated levels of"/>
  <result pre="VF, ventricular fibrillation; VT, ventricular tachycardia. Myocardial injury and myocarditis" exact="Acute" post="myocardial injury, as evidenced by elevated levels of cardiac"/>
  <result pre="study of 191 patients with COVID-19, 33 patients (17%) had" exact="acute" post="cardiac injury, of whom 32Â died19. In a subsequent"/>
  <result pre="cardiac troponin T was 37.5%, whereas, in patients with underlying" exact="cardiovascular" post="comorbidities plus elevated levels of cardiac troponin T, it"/>
  <result pre="high levels of C-reactive protein. Whether typical clinical features of" exact="myocarditis" post="were present in patients who had elevated levels of"/>
  <result pre="on echocardiography and/or electrocardiogram did not have typical signs of" exact="myocarditis" post="such as segmental wall motion abnormality or reduced left"/>
  <result pre="ventricular (LV) ejection fraction (LVEF), suggesting that myocardial injury was" exact="secondary" post="to systemic causes rather than a result of direct"/>
  <result pre="ejection fraction (LVEF), suggesting that myocardial injury was secondary to" exact="systemic" post="causes rather than a result of direct viral infection"/>
  <result pre="secondary to systemic causes rather than a result of direct" exact="viral infection" post="of the heart53. By contrast, several case reports have"/>
  <result pre="to systemic causes rather than a result of direct viral" exact="infection" post="of the heart53. By contrast, several case reports have"/>
  <result pre="By contrast, several case reports have described typical signs of" exact="myocarditis" post="in patients with COVID-19. A woman aged 53Â years"/>
  <result pre="injury, as evidenced by elevated levels of cardiac biomarkers and" exact="diffuse" post="ST segment elevation on the electrocardiogram, had diffuse biventricular"/>
  <result pre="biomarkers and diffuse ST segment elevation on the electrocardiogram, had" exact="diffuse" post="biventricular hypokinesis on cardiac MRI, especially in the apical"/>
  <result pre="dysfunction (LVEFâ€‰=â€‰35%)55. MRI data also revealed marked biventricular interstitial oedema," exact="diffuse" post="late gadolinium enhancement and circumferential pericardial effusion, features that"/>
  <result pre="marked biventricular interstitial oedema, diffuse late gadolinium enhancement and circumferential" exact="pericardial effusion," post="features that are consistent with acute myocarditis. Furthermore, in"/>
  <result pre="enhancement and circumferential pericardial effusion, features that are consistent with" exact="acute" post="myocarditis. Furthermore, in a man aged 37 years with"/>
  <result pre="acute myocarditis. Furthermore, in a man aged 37 years with" exact="chest" post="pain and ST segment elevation, echocardiography revealed an enlarged"/>
  <result pre="with chest pain and ST segment elevation, echocardiography revealed an" exact="enlarged heart" post="(LV diastolic dimensionâ€‰=â€‰58â€‰mm) and LV dysfunction (LVEFâ€‰=â€‰27%)56. This patient"/>
  <result pre="chest pain and ST segment elevation, echocardiography revealed an enlarged" exact="heart" post="(LV diastolic dimensionâ€‰=â€‰58â€‰mm) and LV dysfunction (LVEFâ€‰=â€‰27%)56. This patient"/>
  <result pre="LV dysfunction (LVEFâ€‰=â€‰27%)56. This patient was diagnosed with COVID-19-induced fulminant" exact="myocarditis" post="and treated with methylprednisolone. Cardiac size and function recovered"/>
  <result pre="was diagnosed with COVID-19-induced fulminant myocarditis and treated with methylprednisolone." exact="Cardiac" post="size and function recovered to normal after 1 week"/>
  <result pre="(LV diastolic dimensionâ€‰=â€‰42â€‰mm, LVEFâ€‰=â€‰66%). Histological evidence of myocardial injury or" exact="myocarditis" post="in COVID-19 is also limited. An autopsy of a"/>
  <result pre="a patient with COVID-19 and ARDS who died of a" exact="sudden cardiac arrest" post="showed no evidence of myocardial structural involvement, suggesting that"/>
  <result pre="patient with COVID-19 and ARDS who died of a sudden" exact="cardiac arrest" post="showed no evidence of myocardial structural involvement, suggesting that"/>
  <result pre="reports have also revealed the presence of mild inflammation and" exact="viral" post="RNA in the hearts of patients with COVID-19 (refs59,60)."/>
  <result pre="of patients with COVID-19 (refs59,60). However, whether these patients had" exact="myocarditis" post="or whether the findings were a consequence of systemic"/>
  <result pre="had myocarditis or whether the findings were a consequence of" exact="systemic" post="inflammation remains unclear. Our understanding of the pathophysiology underlying"/>
  <result pre="mechanisms of entry into the host cell4,12,43 and that the" exact="heart" post="expresses high levels of ACE2 (refs15,61). In a report"/>
  <result pre="described autopsy samples from ten Canadian patients with SARS, the" exact="viral" post="RNA of SARS-CoV was detected in 35% of the"/>
  <result pre="viral RNA of SARS-CoV was detected in 35% of the" exact="heart" post="samples, but the infected cell types were unknown62. A"/>
  <result pre="damage was also detected, suggesting that SARS-CoV can infect the" exact="heart" post="directly62. Taken together, these findings suggest that myocardial injury"/>
  <result pre="evidence, myocardial injury seems to be largely attributable to advanced" exact="systemic" post="inflammation. SARS-CoV-2 might also infect the myocardium directly, resulting"/>
  <result pre="inflammation. SARS-CoV-2 might also infect the myocardium directly, resulting in" exact="viral" post="myocarditis in a small proportion of patients with COVID-19."/>
  <result pre="SARS-CoV-2 might also infect the myocardium directly, resulting in viral" exact="myocarditis" post="in a small proportion of patients with COVID-19. Acute"/>
  <result pre="viral myocarditis in a small proportion of patients with COVID-19." exact="Acute coronary syndrome" post="As with other infectious diseases, including SARS and influenza,"/>
  <result pre="in a small proportion of patients with COVID-19. Acute coronary" exact="syndrome" post="As with other infectious diseases, including SARS and influenza,"/>
  <result pre="of patients with COVID-19. Acute coronary syndrome As with other" exact="infectious diseases," post="including SARS and influenza, COVID-19 can trigger ACS44,63â€&quot;66. In"/>
  <result pre="China, a small proportion of patients with COVID-19 presented with" exact="chest" post="pain on admission to hospital, but the characteristics of"/>
  <result pre="pain on admission to hospital, but the characteristics of the" exact="chest" post="pain were not described17,18. In a case series from"/>
  <result pre="COVID-19 and ST segment elevation, which is indicative of potential" exact="acute" post="myocardial infarction, five of the six patients with myocardial"/>
  <result pre="and ST segment elevation, which is indicative of potential acute" exact="myocardial infarction," post="five of the six patients with myocardial infarction required"/>
  <result pre="potential acute myocardial infarction, five of the six patients with" exact="myocardial infarction" post="required percutaneous coronary intervention66. In a case series from"/>
  <result pre="Italy involving 28 patients with COVID-19 and ST segment elevation" exact="myocardial infarction," post="assessment by coronary angiography showed that 17 patients had"/>
  <result pre="culprit lesion that required revascularization52. Of note, ST segment elevation" exact="myocardial infarction" post="was the first clinical manifestation of COVID-19 in 24Â"/>
  <result pre="observations suggest that COVID-19 can cause ACS even in the" exact="absence of" post="substantial systemic inflammation. However, the incidence of ACS in"/>
  <result pre="COVID-19 can cause ACS even in the absence of substantial" exact="systemic" post="inflammation. However, the incidence of ACS in patients with"/>
  <result pre="cities during the COVID-19 outbreak, the number of cases of" exact="acute" post="myocardial infarction among patients with COVID-19 might be underestimated"/>
  <result pre="during the COVID-19 outbreak, the number of cases of acute" exact="myocardial infarction" post="among patients with COVID-19 might be underestimated in early"/>
  <result pre="might involve plaque rupture, coronary spasm or microthrombi owing to" exact="systemic" post="inflammation or cytokine storm67,68. For example, activated macrophages secrete"/>
  <result pre="triggers thrombus formation when the plaque ruptures67. Direct endothelial or" exact="vascular" post="injury caused by SARS-CoV-2 infection might also increase the"/>
  <result pre="plaque ruptures67. Direct endothelial or vascular injury caused by SARS-CoV-2" exact="infection" post="might also increase the risk of thrombus formation and"/>
  <result pre="outbreak in Italy, Spain and the USA was actually significantly" exact="lower" post="than during pre-COVID-19 periods, with a reported 42â€&quot;48% reduction"/>
  <result pre="segment elevation myocardial infarction70â€&quot;73. By contrast, the incidence of out-of-hospital" exact="cardiac arrest" post="increased during the COVID-19 outbreak in Italy, which was"/>
  <result pre="accordance with the finding that the number of patients with" exact="myocardial infarction" post="seeking urgent hospital care declined by &amp;gt;50% during the"/>
  <result pre="as reported in an extensive global survey by the ESC75." exact="Heart" post="failure In an early study from Wuhan involving 799"/>
  <result pre="failure In an early study from Wuhan involving 799 patients," exact="heart" post="failure was one of the most commonly observed complications"/>
  <result pre="24% in all patients and 49% in patients who died76." exact="Elevated" post="levels of amino-terminal pro-B-type natriuretic peptide were identified in"/>
  <result pre="died)76. Similarly, in another study of 191 patients in Wuhan," exact="heart" post="failure was identified in 23% of all patients and"/>
  <result pre="and in 52% of patients who died19. The aetiology of" exact="acute" post="or decompensated heart failure in COVID-19 has not been"/>
  <result pre="of patients who died19. The aetiology of acute or decompensated" exact="heart" post="failure in COVID-19 has not been studied77. Given that"/>
  <result pre="to be older and to have pre-existing comorbidities such as" exact="coronary artery disease," post="hypertension and diabetes, heart failure might be the result"/>
  <result pre="be older and to have pre-existing comorbidities such as coronary" exact="artery disease," post="hypertension and diabetes, heart failure might be the result"/>
  <result pre="and to have pre-existing comorbidities such as coronary artery disease," exact="hypertension" post="and diabetes, heart failure might be the result of"/>
  <result pre="pre-existing comorbidities such as coronary artery disease, hypertension and diabetes," exact="heart" post="failure might be the result of an exacerbation of"/>
  <result pre="In particular, elderly patients with reduced diastolic function might develop" exact="heart" post="failure with preserved EF during the course of COVID-19,"/>
  <result pre="tachycardia, excessive hydration and impaired renal function77. In patients with" exact="heart" post="failure with preserved ejection fraction, cardiac MRI might help"/>
  <result pre="MRI might help to detect changes induced by COVID-19 (refs78,79)." exact="Acute" post="myocardial injury and ACS triggered by COVID-19 can also"/>
  <result pre="injury and ACS triggered by COVID-19 can also aggravate pre-existing" exact="heart" post="disease or provoke contractile dysfunction. In the advanced stages"/>
  <result pre="and ACS triggered by COVID-19 can also aggravate pre-existing heart" exact="disease" post="or provoke contractile dysfunction. In the advanced stages of"/>
  <result pre="stages of COVID-19, the response of the immune system to" exact="infection" post="might trigger the development of stress-induced cardiomyopathy or cytokine-related"/>
  <result pre="immune system to infection might trigger the development of stress-induced" exact="cardiomyopathy" post="or cytokine-related myocardial dysfunction, as with sepsis-associated cardiac dysfunction80,81."/>
  <result pre="as with sepsis-associated cardiac dysfunction80,81. Given that COVID-19 primarily causes" exact="respiratory" post="symptoms and viral pneumonia with bilateral, peripheral and lower"/>
  <result pre="cardiac dysfunction80,81. Given that COVID-19 primarily causes respiratory symptoms and" exact="viral pneumonia" post="with bilateral, peripheral and lower lung distribution, the pulmonary"/>
  <result pre="dysfunction80,81. Given that COVID-19 primarily causes respiratory symptoms and viral" exact="pneumonia" post="with bilateral, peripheral and lower lung distribution, the pulmonary"/>
  <result pre="COVID-19 primarily causes respiratory symptoms and viral pneumonia with bilateral," exact="peripheral" post="and lower lung distribution, the pulmonary oedema that is"/>
  <result pre="causes respiratory symptoms and viral pneumonia with bilateral, peripheral and" exact="lower" post="lung distribution, the pulmonary oedema that is observed in"/>
  <result pre="viral pneumonia with bilateral, peripheral and lower lung distribution, the" exact="pulmonary" post="oedema that is observed in these patients, which is"/>
  <result pre="given that approximately 25% of patients hospitalized with COVID-19 develop" exact="heart" post="failure, the potential contribution of pulmonary congestion by heart"/>
  <result pre="hospitalized with COVID-19 develop heart failure, the potential contribution of" exact="pulmonary" post="congestion by heart failure should be taken into consideration77."/>
  <result pre="develop heart failure, the potential contribution of pulmonary congestion by" exact="heart" post="failure should be taken into consideration77. Additional haemodynamic data"/>
  <result pre="taken into consideration77. Additional haemodynamic data from patients with COVID-19-related" exact="respiratory" post="failure are needed to validate this involvement. Arrhythmias and"/>
  <result pre="with COVID-19-related respiratory failure are needed to validate this involvement." exact="Arrhythmias" post="and sudden cardiac arrest Arrhythmias and sudden cardiac arrest"/>
  <result pre="respiratory failure are needed to validate this involvement. Arrhythmias and" exact="sudden cardiac arrest" post="Arrhythmias and sudden cardiac arrest are common manifestations of"/>
  <result pre="failure are needed to validate this involvement. Arrhythmias and sudden" exact="cardiac arrest" post="Arrhythmias and sudden cardiac arrest are common manifestations of"/>
  <result pre="needed to validate this involvement. Arrhythmias and sudden cardiac arrest" exact="Arrhythmias" post="and sudden cardiac arrest are common manifestations of COVID-19."/>
  <result pre="validate this involvement. Arrhythmias and sudden cardiac arrest Arrhythmias and" exact="sudden cardiac arrest" post="are common manifestations of COVID-19. Heart palpitations have been"/>
  <result pre="this involvement. Arrhythmias and sudden cardiac arrest Arrhythmias and sudden" exact="cardiac arrest" post="are common manifestations of COVID-19. Heart palpitations have been"/>
  <result pre="Arrhythmias and sudden cardiac arrest are common manifestations of COVID-19." exact="Heart" post="palpitations have been reported to be the main presenting"/>
  <result pre="138 patients with COVID-19 in Wuhan, China, the presence of" exact="cardiac arrhythmia" post="was reported in 17% of all patients (44% of"/>
  <result pre="patients with COVID-19 in Wuhan, China, the presence of cardiac" exact="arrhythmia" post="was reported in 17% of all patients (44% of"/>
  <result pre="of patients in the ICU), but the specific types of" exact="arrhythmia" post="were not recorded18. In another study in Wuhan involving"/>
  <result pre="elevated levels of troponin T were more likely to develop" exact="malignant" post="arrhythmias, such as ventricular tachycardia and fibrillation, than those"/>
  <result pre="T were more likely to develop malignant arrhythmias, such as" exact="ventricular tachycardia" post="and fibrillation, than those with normal levels of troponin"/>
  <result pre="arrhythmias remains uncertain given that arrhythmias, such as atrial and" exact="ventricular tachycardia" post="and fibrillation, can be triggered by myocardial injury or"/>
  <result pre="and fibrillation, can be triggered by myocardial injury or other" exact="systemic" post="causes such as fever, sepsis, hypoxia and electrolyte abnormalities24,83."/>
  <result pre="myocardial injury or other systemic causes such as fever, sepsis," exact="hypoxia" post="and electrolyte abnormalities24,83. Furthermore, patients with advanced COVID-19 are"/>
  <result pre="in some patients (described in detailÂ below)13,41. Coagulation abnormalities and" exact="thrombosis" post="COVID-19 is associated with coagulation abnormalities, which can result"/>
  <result pre="41 patients with COVID-19 in Wuhan, only 5% had a" exact="low platelet count" post="(&amp;lt;100â€‰Ã—â€‰109 cells per litre) and the prolongation of prothrombin"/>
  <result pre="coagulation abnormalities that typically do not meet the criteria of" exact="disseminated intravascular coagulation" post="established by the International Society on Thrombosis and Haemostasis86,"/>
  <result pre="of disseminated intravascular coagulation established by the International Society on" exact="Thrombosis" post="and Haemostasis86, but nevertheless might contribute to the development"/>
  <result pre="but nevertheless might contribute to the development of the diverse" exact="cardiovascular" post="manifestations of COVID-19. Clinical observations of increased thromboembolic events"/>
  <result pre="the presence of a hypercoagulable state. Venous thromboembolism, which includes" exact="deep vein thrombosis" post="and pulmonary embolism, is a common complication in critically"/>
  <result pre="of a hypercoagulable state. Venous thromboembolism, which includes deep vein" exact="thrombosis" post="and pulmonary embolism, is a common complication in critically"/>
  <result pre="hypercoagulable state. Venous thromboembolism, which includes deep vein thrombosis and" exact="pulmonary embolism," post="is a common complication in critically ill patients with"/>
  <result pre="critically ill patients with COVID-19. An autopsy study revealed that" exact="deep vein thrombosis" post="was present in 7 of 12 patients who died"/>
  <result pre="patients with COVID-19. An autopsy study revealed that deep vein" exact="thrombosis" post="was present in 7 of 12 patients who died"/>
  <result pre="7 of 12 patients who died with COVID-19 in whom" exact="venous thromboembolism" post="was not suspected before death, whereas pulmonary embolism was"/>
  <result pre="in whom venous thromboembolism was not suspected before death, whereas" exact="pulmonary embolism" post="was identified in 4 of the 12 patients59. Arterial"/>
  <result pre="years who presented to the same hospital with large-vessel ischaemic" exact="stroke" post="and who all tested positive for SARS-CoV-2 infection87. Furthermore,"/>
  <result pre="stroke and who all tested positive for SARS-CoV-2 infection87. Furthermore," exact="acute" post="limb ischaemia was also reported in 20 patients with"/>
  <result pre="who all tested positive for SARS-CoV-2 infection87. Furthermore, acute limb" exact="ischaemia" post="was also reported in 20 patients with COVID-19 (90%"/>
  <result pre="series from Italy88. All 20 patients were diagnosed with COVID-19-related" exact="pneumonia" post="before acute limb ischaemia was detected. The mechanisms underlying"/>
  <result pre="Italy88. All 20 patients were diagnosed with COVID-19-related pneumonia before" exact="acute" post="limb ischaemia was detected. The mechanisms underlying these coagulation"/>
  <result pre="20 patients were diagnosed with COVID-19-related pneumonia before acute limb" exact="ischaemia" post="was detected. The mechanisms underlying these coagulation abnormalities, particularly"/>
  <result pre="medications and investigational therapies given to these patients might promote" exact="thrombosis" post="or bleeding events through drugâ€&quot;drug interactions with antiplatelet agents"/>
  <result pre="investigational therapies given to these patients might promote thrombosis or" exact="bleeding" post="events through drugâ€&quot;drug interactions with antiplatelet agents and anticoagulants41."/>
  <result pre="and anticoagulants41. A retrospective study in New York showed that" exact="systemic" post="anticoagulation was associated with prolonged survival in patients hospitalized"/>
  <result pre="hospitalized with COVID-19 (ref.89). Among 2,773 patients, 786 (28%) received" exact="systemic" post="anticoagulation. The median survival time of patients who were"/>
  <result pre="in China also showed reduced mortality in patients with COVID-19-associated" exact="coagulopathy" post="who were treated with prophylactic heparin90. Importantly, findings from"/>
  <result pre="with prophylactic heparin90. Importantly, findings from these retrospective studies are" exact="limited" post="by potential selection bias, the presence of confounding factors"/>
  <result pre="the protective effect of anticoagulation therapy in patients with COVID-19." exact="Kawasaki disease" post="Children are thought to be less susceptible than adults"/>
  <result pre="protective effect of anticoagulation therapy in patients with COVID-19. Kawasaki" exact="disease" post="Children are thought to be less susceptible than adults"/>
  <result pre="of eight children (aged 4â€&quot;14 years) presenting with a hyperinflammatory" exact="syndrome" post="with features of Kawasaki disease, five of whom tested"/>
  <result pre="4â€&quot;14 years) presenting with a hyperinflammatory syndrome with features of" exact="Kawasaki disease," post="five of whom tested positive for SARS-CoV-2 or were"/>
  <result pre="from family members26. Clinical presentations included fever, variable rash, conjunctivitis," exact="peripheral" post="oedema, extremity pain and severe gastrointestinal symptoms. A common"/>
  <result pre="echocardiography was echo-bright coronary vessels, which progressed to a giant" exact="coronary aneurysm" post="in one patient. Furthermore, researchers in Bergamo, Italy, found"/>
  <result pre="was echo-bright coronary vessels, which progressed to a giant coronary" exact="aneurysm" post="in one patient. Furthermore, researchers in Bergamo, Italy, found"/>
  <result pre="Italy, found a 30-fold increase in the incidence of Kawasaki-like" exact="disease" post="among children during the peak of the pandemic92. These"/>
  <result pre="a higher rate of cardiac involvement than patients diagnosed with" exact="Kawasaki disease" post="before the pandemic. Together, these early clinical findings are"/>
  <result pre="higher rate of cardiac involvement than patients diagnosed with Kawasaki" exact="disease" post="before the pandemic. Together, these early clinical findings are"/>
  <result pre="findings are suggestive of a new phenomenon caused by SARS-CoV-2" exact="infection" post="in children that can lead to a hyperinflammatory syndrome"/>
  <result pre="SARS-CoV-2 infection in children that can lead to a hyperinflammatory" exact="syndrome" post="with features that are similar to those of Kawasaki"/>
  <result pre="hyperinflammatory syndrome with features that are similar to those of" exact="Kawasaki disease," post="including coronary artery abnormalities. Immunocompromised patients In general, patients"/>
  <result pre="patients with depressed immunity are at a higher risk of" exact="infectious diseases." post="The effect of COVID-19 on the cardiovascular system in"/>
  <result pre="risk of infectious diseases. The effect of COVID-19 on the" exact="cardiovascular" post="system in immunocompromised patients, such as those with cancer"/>
  <result pre="the cardiovascular system in immunocompromised patients, such as those with" exact="cancer" post="or those who have undergone organ transplantation, is largely"/>
  <result pre="or those who have undergone organ transplantation, is largely unknown." exact="Heart" post="transplantation recipients might be at higher risk of COVID-19"/>
  <result pre="COVID-19 owing to their immunosuppressed state combined with their baseline" exact="cardiovascular" post="disorders14,93. COVID-19 has been reported in two heart transplantation"/>
  <result pre="their baseline cardiovascular disorders14,93. COVID-19 has been reported in two" exact="heart" post="transplantation recipients from China, both of whom made a"/>
  <result pre="those of non-immunosuppressed patients. In a retrospective case series of" exact="heart" post="transplantation recipients with COVID-19 admitted to hospitals in Michigan,"/>
  <result pre="April 2020, 13 patients were identified, all of whom were" exact="African" post="American men95. Six patients required admission to the ICU"/>
  <result pre="2020, 13 patients were identified, all of whom were African" exact="American" post="men95. Six patients required admission to the ICU and"/>
  <result pre="hospitalization. Of note, the clinical presentation and laboratory markers of" exact="disease" post="severity of these patients were not distinct from those"/>
  <result pre="to preserve allograft function. However, another case series involving 28" exact="heart" post="transplantation recipients with COVID-19 in New York reported higher"/>
  <result pre="complications in these individuals than in the general population96. A" exact="total" post="of 22 patients were hospitalized, of whom 7 patients"/>
  <result pre="of troponin T (&amp;gt;0.022â€‰ng/ml). These findings suggest that recipients of" exact="heart" post="transplantation are at high risk of severe complications from"/>
  <result pre="and whether immunosuppressive treatments have harmful (or protective) effects on" exact="disease" post="progression needs to be assessed in large-scale studies. Another"/>
  <result pre="to be assessed in large-scale studies. Another important point regarding" exact="heart" post="transplantation is the need to screen for COVID-19. Given"/>
  <result pre="need to screen for COVID-19. Given that individuals with SARS-CoV-2" exact="infection" post="might be asymptomatic, routine screening of donor tissues is"/>
  <result pre="transplantation will also be required to avoid worsening of subclinical" exact="infection" post="after starting immunosuppression. As with patients with CVD, patients"/>
  <result pre="after starting immunosuppression. As with patients with CVD, patients with" exact="cancer" post="are thought to be at higher risk of severe"/>
  <result pre="be attributable to suppressed immunity by chemotherapy, the presence of" exact="cardiovascular" post="risk factors (such as hypertension and diabetes), cardiotoxicity of"/>
  <result pre="by chemotherapy, the presence of cardiovascular risk factors (such as" exact="hypertension" post="and diabetes), cardiotoxicity of cancer treatment and/or cardiovascular damage"/>
  <result pre="cardiovascular risk factors (such as hypertension and diabetes), cardiotoxicity of" exact="cancer" post="treatment and/or cardiovascular damage by COVID-19, combined with their"/>
  <result pre="(such as hypertension and diabetes), cardiotoxicity of cancer treatment and/or" exact="cardiovascular" post="damage by COVID-19, combined with their impaired baseline condition97."/>
  <result pre="during the pandemic is to balance the risk of SARS-CoV-2" exact="infection" post="with the need to provide timely cancer treatment. Clinicians"/>
  <result pre="risk of SARS-CoV-2 infection with the need to provide timely" exact="cancer" post="treatment. Clinicians need to determine the optimal timing of"/>
  <result pre="to determine the optimal timing of treatment in patients with" exact="cancer" post="and cardiovascular comorbidities, especially if they are infected with"/>
  <result pre="the optimal timing of treatment in patients with cancer and" exact="cardiovascular" post="comorbidities, especially if they are infected with or exposed"/>
  <result pre="exposed to SARS-CoV-2. Routine COVID-19 screening might be necessary before" exact="cancer" post="treatment to avoid worsening of a subclinical infection. ACE2"/>
  <result pre="treatment to avoid worsening of a subclinical infection. ACE2 and" exact="cardiovascular" post="manifestations The mechanisms underlying the development of COVID-19-related cardiovascular"/>
  <result pre="and cardiovascular manifestations The mechanisms underlying the development of COVID-19-related" exact="cardiovascular" post="injury are not known. ACE2 expression is thought to"/>
  <result pre="the biological mechanism underlying tissue-specific infection. As with SARS-CoV, SARS-CoV-2" exact="infection" post="is triggered by binding of viral SÂ protein to"/>
  <result pre="As with SARS-CoV, SARS-CoV-2 infection is triggered by binding of" exact="viral" post="SÂ protein to human ACE2, whereas TMPRSS2 inducesÂ SÂ"/>
  <result pre="ACE2 is known to have crucial roles in both the" exact="cardiovascular" post="system and the immune system61,100. ACE2 is a part"/>
  <result pre="the RAAS and is involved in the development of diabetes," exact="hypertension" post="and heart failure. At the tissue level, ACE2 is"/>
  <result pre="RAAS and is involved in the development of diabetes, hypertension" exact="and heart" post="failure. At the tissue level, ACE2 is highly expressed"/>
  <result pre="and is involved in the development of diabetes, hypertension and" exact="heart" post="failure. At the tissue level, ACE2 is highly expressed"/>
  <result pre="tissue level, ACE2 is highly expressed in the lungs, kidneys," exact="heart" post="and blood vessels61,100. According to bulk RNA sequencing data"/>
  <result pre="Expression (GTEx) project V8, the expression of ACE2 in the" exact="heart" post="and coronary arteries is even higher thanÂ in the"/>
  <result pre="the single-cell level, ACE2 is highlyÂ expressedÂ in pericytes of" exact="adult" post="human hearts102. Single-cell RNA sequencing data have also revealed"/>
  <result pre="(especially those in the right ventricle) express ACE2 at a" exact="lower" post="level than pericytes and that neither pericytes nor cardiomyocytes"/>
  <result pre="pathway. Therefore, SARS-CoV-2 might be capable of directly infecting multiple" exact="cardiovascular" post="cell types, including cardiomyocytes, endothelial cells and pericytes. Importantly,"/>
  <result pre="of the virus into a cell, and the efficiency of" exact="viral" post="replication and release might also have a role in"/>
  <result pre="in host cell infection. ToÂ date, clinical evidence of direct" exact="viral infection" post="of cardiomyocytes has not been found. Given that myocarditis"/>
  <result pre="host cell infection. ToÂ date, clinical evidence of direct viral" exact="infection" post="of cardiomyocytes has not been found. Given that myocarditis"/>
  <result pre="viral infection of cardiomyocytes has not been found. Given that" exact="myocarditis" post="related to SARS-CoV-2 infection is rare23,53, the interaction between"/>
  <result pre="has not been found. Given that myocarditis related to SARS-CoV-2" exact="infection" post="is rare23,53, the interaction between SARS-CoV-2 and ACE2 might"/>
  <result pre="rare23,53, the interaction between SARS-CoV-2 and ACE2 might affect the" exact="cardiovascular" post="system in an indirect manner61,100. Genome-wide association studies would"/>
  <result pre="In a mouse model of SARS, ACE2 levels in the" exact="heart" post="were significantly reduced after SARS-CoV infection62. In addition, a"/>
  <result pre="effect in the lungs. ACE2 is expressed primarily in alveolar" exact="epithelial" post="type II cells in the normal adult lung110â€&quot;112. These"/>
  <result pre="in the lungs. ACE2 is expressed primarily in alveolar epithelial" exact="type II" post="cells in the normal adult lung110â€&quot;112. These cells produce"/>
  <result pre="primarily in alveolar epithelial type II cells in the normal" exact="adult" post="lung110â€&quot;112. These cells produce surfactant proteins that reduce surface"/>
  <result pre="collapsing. In a mouse model of ARDS, Ace2 knockout exacerbated" exact="acute" post="lung injury, whereas treatment with recombinant ACE2 rescued lung"/>
  <result pre="with recombinant ACE2 rescued lung damage106. Therefore, like SARS-CoV, SARS-CoV-2" exact="infection" post="might result in the downregulation of ACE2, which can"/>
  <result pre="many diseases and is a common treatment target for various" exact="cardiovascular" post="disorders61,100,113. ACE2 inactivates angiotensin II by converting angiotensin II"/>
  <result pre="exogenous administration of recombinant human ACE2 (rhACE2) can prevent SARS-CoV-2" exact="infection" post="by acting as a decoy114. The investigators demonstrated that"/>
  <result pre="decoy114. The investigators demonstrated that clinical-grade rhACE2 can reduce SARS-CoV-2" exact="infection" post="in cell culture and in engineered human blood vessel"/>
  <result pre="might be a promising approach to treat patients with COVID-19-related" exact="cardiovascular" post="disorders114. Broad tissue tropism of SARS-CoV-2 Although SARS-CoV-2 preferentially"/>
  <result pre="tropism of SARS-CoV-2 Although SARS-CoV-2 preferentially infects the lungs and" exact="respiratory" post="tract like other respiratory viruses, COVID-19 can cause a"/>
  <result pre="SARS-CoV-2 preferentially infects the lungs and respiratory tract like other" exact="respiratory" post="viruses, COVID-19 can cause a diverse range of extrapulmonary"/>
  <result pre="CVD, stroke, seizures, liver damage, renal dysfunction and gastrointestinal symptoms117." exact="Systemic" post="hyperinflammation induced by viral pneumonia is likely to have"/>
  <result pre="damage, renal dysfunction and gastrointestinal symptoms117. Systemic hyperinflammation induced by" exact="viral pneumonia" post="is likely to have an important role in the"/>
  <result pre="renal dysfunction and gastrointestinal symptoms117. Systemic hyperinflammation induced by viral" exact="pneumonia" post="is likely to have an important role in the"/>
  <result pre="but numerous studies have also reported histological evidence of direct" exact="viral infection" post="in non-respiratory organs such as the heart, brain, liver"/>
  <result pre="numerous studies have also reported histological evidence of direct viral" exact="infection" post="in non-respiratory organs such as the heart, brain, liver"/>
  <result pre="high concentrations in all patients, 5 patients also had high" exact="viral" post="RNA titres in the heart, liver or kidney59. Similarly,"/>
  <result pre="who died with COVID-19 are not just a consequence of" exact="systemic" post="inflammation or cytokine storm, but might also be caused"/>
  <result pre="or cytokine storm, but might also be caused by direct" exact="infection" post="of numerous organ systems by SARS-CoV-2. Mechanistically, the broad"/>
  <result pre="presence of the novel furin cleavage site, as mentioned above4." exact="Viral" post="targeting of endothelial cells Preliminary histological data from a"/>
  <result pre="history of renal transplantation who died from COVID-19-induced multiorgan failure," exact="viral" post="particles were detected by electron microscopy in endothelial cells"/>
  <result pre="of apoptotic bodies in numerous organs including the lungs, small" exact="bowel" post="and heart69. In another patient who died from COVID-19-related"/>
  <result pre="who died from COVID-19-related multiorgan failure and ST segment elevation" exact="myocardial infarction," post="lymphocytic endotheliitis was observed in the lungs, heart, liver"/>
  <result pre="liver and kidneys69. In the third patient who had mesenteric" exact="ischaemia" post="and underwent resection of the small intestine, histological assessment"/>
  <result pre="level of ACE2 expression, inflammation in the endothelium caused by" exact="infection" post="with SARS-CoV-2 might underlie the diverse clinical manifestations of"/>
  <result pre="and ARBs are commonly used worldwide for the treatment of" exact="hypertension" post="and other CVDs, whether these drugs should be discontinued"/>
  <result pre="the ACC, AHA, Chinese Society of Cardiology, ESC and the" exact="Heart Failure" post="Society of America have issued statements recommending continuation of"/>
  <result pre="ACC, AHA, Chinese Society of Cardiology, ESC and the Heart" exact="Failure" post="Society of America have issued statements recommending continuation of"/>
  <result pre="positive COVID-19 test, suggesting that these agents do not affect" exact="susceptibility to" post="SARS-CoV-2 infection. Furthermore, the use of these agents was"/>
  <result pre="evidence of upregulated ACE2 by RAAS inhibitors in patients with" exact="heart" post="failure135, aortic stenosis136, atrial fibrillation137 or coronary artery disease138."/>
  <result pre="has been found to show that upregulation of ACE2 affects" exact="susceptibility to" post="viral infection113. Furthermore, as shown in Ace2-knockout mice106â€&quot;109 and"/>
  <result pre="found to show that upregulation of ACE2 affects susceptibility to" exact="viral" post="infection113. Furthermore, as shown in Ace2-knockout mice106â€&quot;109 and rhACE2"/>
  <result pre="to angiotensin (1â€&quot;7). Therefore, ACE2 has a protective effect against" exact="cardiovascular disease" post="and lung injury. In the setting of coronavirus disease"/>
  <result pre="angiotensin (1â€&quot;7). Therefore, ACE2 has a protective effect against cardiovascular" exact="disease" post="and lung injury. In the setting of coronavirus disease"/>
  <result pre="cardiovascular disease and lung injury. In the setting of coronavirus" exact="disease" post="2019, downregulation of ACE2 by severe acute respiratory syndrome"/>
  <result pre="setting of coronavirus disease 2019, downregulation of ACE2 by severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) infection might be involved"/>
  <result pre="of coronavirus disease 2019, downregulation of ACE2 by severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) infection might be involved in"/>
  <result pre="coronavirus disease 2019, downregulation of ACE2 by severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) infection might be involved in mediating"/>
  <result pre="of ACE2 by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" exact="infection" post="might be involved in mediating cardiovascular damage. ARB, angiotensin"/>
  <result pre="syndrome coronavirus 2 (SARS-CoV-2) infection might be involved in mediating" exact="cardiovascular" post="damage. ARB, angiotensin II receptor blocker. Cardiovascular effects of"/>
  <result pre="which existing medications that have already been approved for a" exact="disease" post="are tested for a new condition, is currently the"/>
  <result pre="some of the drugs under investigation have known or unknown" exact="cardiovascular" post="adverse effects142 or might be involved in drugâ€&quot;drug or"/>
  <result pre="in drugâ€&quot;drug or drugâ€&quot;disease interactions41,140 (TableÂ 2). Table 2 Adverse" exact="cardiovascular" post="effects of potential drugs to treat COVID-19 Drug Mechanism"/>
  <result pre="of S proteinâ€&quot;ACE2 interaction and membrane fusion Not common, but" exact="limited" post="clinical data Inhibitors of synthesis of non-structural proteins Lopinavirâ€&quot;ritonavir"/>
  <result pre="Atrioventricular block and cytochrome P450 3A4-related drugâ€&quot;drug interaction Inhibitors of" exact="viral" post="RNA replication Favipiravir Inhibition of RdRP Not common, but"/>
  <result pre="viral RNA replication Favipiravir Inhibition of RdRP Not common, but" exact="limited" post="clinical data Remdesivir Inhibition of RdRP Not common, but"/>
  <result pre="limited clinical data Remdesivir Inhibition of RdRP Not common, but" exact="limited" post="clinical data Ribavirin Inhibition of RdRP Not common Others"/>
  <result pre="with chloroquine or hydroxychloroquine QT interval prolongation Tocilizumab IL-6 inhibition" exact="Hypertension" post="ACE2, angiotensin-converting enzyme 2; COVID-19, coronavirus disease 2019; RdRP,"/>
  <result pre="Tocilizumab IL-6 inhibition Hypertension ACE2, angiotensin-converting enzyme 2; COVID-19, coronavirus" exact="disease" post="2019; RdRP, RNA-dependent RNA polymerase; S protein, spike protein."/>
  <result pre="lysosomal activity41. Both drugs are used in the treatment of" exact="malaria" post="and chronic inflammatory diseases such as systemic lupus erythematosus"/>
  <result pre="Both drugs are used in the treatment of malaria and" exact="chronic" post="inflammatory diseases such as systemic lupus erythematosus and rheumatoid"/>
  <result pre="the treatment of malaria and chronic inflammatory diseases such as" exact="systemic" post="lupus erythematosus and rheumatoid arthritis41,146. A French observational study"/>
  <result pre="treatment of malaria and chronic inflammatory diseases such as systemic" exact="lupus erythematosus" post="and rheumatoid arthritis41,146. A French observational study involving 36"/>
  <result pre="involving 550 critically ill patients with COVID-19, mortality was significantly" exact="lower" post="among patients treated with hydroxychloroquine plus standard treatment (which"/>
  <result pre="the groups had an increase in in-hospital mortality, but the" exact="secondary" post="outcome of cardiac arrest was more likely in patients"/>
  <result pre="an increase in in-hospital mortality, but the secondary outcome of" exact="cardiac arrest" post="was more likely in patients receiving both hydroxychloroquine and"/>
  <result pre="patients with COVID-19 might have impaired renal function owing to" exact="systemic" post="illness, frequent electrocardiographic evaluation should be strongly considered in"/>
  <result pre="and therapeutic administration of remdesivir has been shown to improve" exact="pulmonary" post="function and to decrease viral load in a mouse"/>
  <result pre="has been shown to improve pulmonary function and to decrease" exact="viral" post="load in a mouse model of MERS156. In a"/>
  <result pre="course is suggested for patients with milder symptoms. Although prominent" exact="cardiovascular" post="adverse effects associated with remdesivir have not been reported"/>
  <result pre="fixed-dose drug combination used for the prevention and treatment of" exact="HIV infection" post="and works by inhibiting protease activity159. Lopinavir is available"/>
  <result pre="drug combination used for the prevention and treatment of HIV" exact="infection" post="and works by inhibiting protease activity159. Lopinavir is available"/>
  <result pre="lopinavirâ€&quot;ritonavir treatment group than in the standard group, but adverse" exact="cardiovascular" post="effects were not reported in either group159. Nevertheless, lopinavirâ€&quot;ritonavir"/>
  <result pre="with COVID-19 because this drug combination might interact with common" exact="cardiovascular" post="drugs that are metabolized by cytochrome P450 3A4, including"/>
  <result pre="pathophysiological mechanisms underlying SARS can be used to understand the" exact="disease" post="processes involved in COVID-19. Mechanistically, the interaction between the"/>
  <result pre="and ACE2 is likely to have a central role in" exact="disease" post="pathogenesis, especially in cardiovascular manifestations of this disease, and"/>
  <result pre="to have a central role in disease pathogenesis, especially in" exact="cardiovascular" post="manifestations of this disease, and this interaction is a"/>
  <result pre="rating161,162. Second, the use of animal models to mimic the" exact="disease" post="process is associated with numerous challenges163â€&quot;165. Given that cellular"/>
  <result pre="ACE2, other animal species that are naturally susceptible to SARS-CoV-2" exact="infection" post="(such as ferrets, hamsters and non-human primates)164,165,167â€&quot;170 or in"/>
  <result pre="interactions, health-care delivery and the global economy continues to mount." exact="Reduced" post="physical activity owing to lockdown measures might also contribute"/>
  <result pre="to lockdown measures might also contribute to poor control of" exact="cardiovascular" post="risk factors. Vaccine development is expected to take 12â€&quot;18Â"/>
  <result pre="sequencing data COVID-19 Cell Atlas: https://www.covid19cellatlas.org/ Virus genome GenBank severe" exact="acute" post="respiratory syndrome coronavirus 2 sequence: https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/ China National Center"/>
  <result pre="data COVID-19 Cell Atlas: https://www.covid19cellatlas.org/ Virus genome GenBank severe acute" exact="respiratory" post="syndrome coronavirus 2 sequence: https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/ China National Center for"/>
  <result pre="COVID-19 Cell Atlas: https://www.covid19cellatlas.org/ Virus genome GenBank severe acute respiratory" exact="syndrome" post="coronavirus 2 sequence: https://www.ncbi.nlm.nih.gov/genbank/sars-cov-2-seqs/ China National Center for Bioinformation:"/>
  <result pre="COVID-19 hub: https://www.acc.org/latest-in-cardiology/features/accs-coronavirus-disease-2019-covid-19-hub ESC COVID-19 and cardiology: https://www.escardio.org/Education/COVID-19-and-Cardiology COVID-19, coronavirus" exact="disease" post="2019. Competing interests The authors declare no competing interests."/>
  <result pre="content and reviewed and edited the manuscript before submission. Glossary" exact="Acute respiratory distress syndrome" post="(ARDS). A type of severe, acute respiratory failure characterized"/>
  <result pre="and reviewed and edited the manuscript before submission. Glossary Acute" exact="respiratory" post="distress syndrome (ARDS). A type of severe, acute respiratory"/>
  <result pre="and edited the manuscript before submission. Glossary Acute respiratory distress" exact="syndrome" post="(ARDS). A type of severe, acute respiratory failure characterized"/>
  <result pre="Glossary Acute respiratory distress syndrome (ARDS). A type of severe," exact="acute" post="respiratory failure characterized by bilateral pulmonary infiltrates and severe"/>
  <result pre="Acute respiratory distress syndrome (ARDS). A type of severe, acute" exact="respiratory" post="failure characterized by bilateral pulmonary infiltrates and severe hypoxaemia"/>
  <result pre="(ARDS). A type of severe, acute respiratory failure characterized by" exact="bilateral" post="pulmonary infiltrates and severe hypoxaemia that occurs as a"/>
  <result pre="A type of severe, acute respiratory failure characterized by bilateral" exact="pulmonary" post="infiltrates and severe hypoxaemia that occurs as a result"/>
  <result pre="can be triggered by a variety of factors such as" exact="infection" post="and drugs. Tissue tropism The ability of a given"/>
  <result pre="to infect specific cell or tissue types of a host." exact="Kawasaki disease" post="An acute febrile illness of unknown cause that primarily"/>
  <result pre="infect specific cell or tissue types of a host. Kawasaki" exact="disease" post="An acute febrile illness of unknown cause that primarily"/>
  <result pre="cell or tissue types of a host. Kawasaki disease An" exact="acute" post="febrile illness of unknown cause that primarily affects children"/>
  <result pre="rate The proportion of people who die from a certain" exact="disease" post="among all individuals diagnosed with the disease over a"/>
  <result pre="from a certain disease among all individuals diagnosed with the" exact="disease" post="over a certain period of time. References References 1.ZhouPet"/>
  <result pre="over a certain period of time. References References 1.ZhouPet al.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="probable bat originNature202057927027332015507 2.WuFet al.A new coronavirus associated with human" exact="respiratory" post="disease in ChinaNature202057926526932015508 3.LuRet al.Genomic characterisation and epidemiology of"/>
  <result pre="bat originNature202057927027332015507 2.WuFet al.A new coronavirus associated with human respiratory" exact="disease" post="in ChinaNature202057926526932015508 3.LuRet al.Genomic characterisation and epidemiology of 2019"/>
  <result pre="of SARS coronavirusJ. Virol.202094e001272031996437 12.MadjidMSafavi-NaeiniPSolomonSDVardenyOPotential effects of coronaviruses on the" exact="cardiovascular" post="system: a reviewJAMA Cardiol.202010.1001/jamacardio.2020.128632219363 13.ClerkinKJet al.COVID-19 and cardiovascular diseaseCirculation20201411648165532200663"/>
  <result pre="on the cardiovascular system: a reviewJAMA Cardiol.202010.1001/jamacardio.2020.128632219363 13.ClerkinKJet al.COVID-19 and" exact="cardiovascular" post="diseaseCirculation20201411648165532200663 14.DrigginEet al.Cardiovascular considerations for patients, health care workers,"/>
  <result pre="during the COVID-19 pandemicJ. Am. Coll. Cardiol.2020752352237132201335 15.ZhengYYMaYTZhangJYXieXCOVID-19 and the" exact="cardiovascular" post="systemNat. Rev. Cardiol.20201725926032139904 16.HanYet al.CSC expert consensus on principles"/>
  <result pre="on principles of clinical management of patients with severe emergent" exact="cardiovascular" post="diseases during the COVID-19 epidemicCirculation2020141e810e81632216640 17.HuangCet al.Clinical features of"/>
  <result pre="al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJAMA202010.1001/jama.2020.15857259465 19.ZhouFet al.Clinical course and risk factors"/>
  <result pre="ChinaJAMA202010.1001/jama.2020.15857259465 19.ZhouFet al.Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
  <result pre="China: a retrospective cohort studyLancet20203951054106232171076 20.GuanWJet al.Clinical characteristics of coronavirus" exact="disease" post="2019 in ChinaN. Engl. J. Med.20203821708172032109013 21.WuZMcGooganJMCharacteristics of and"/>
  <result pre="J. Med.20203821708172032109013 21.WuZMcGooganJMCharacteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China: summary of a report"/>
  <result pre="a report of 72314 cases from the Chinese Center for" exact="Disease" post="Control and PreventionJAMA202010.1001/jama.2020.264832515813 22.RuanQYangKWangWJiangLSongJClinical predictors of mortality due to"/>
  <result pre="24.GuoTet al.Cardiovascular implications of fatal outcomes of patients with coronavirus" exact="disease" post="2019 (COVID-19)JAMA Cardiol.202010.1001/jamacardio.2020.101732667620 25.ShiSet al.Characteristics and clinical significance of"/>
  <result pre="clinical significance of myocardial injury in patients with severe coronavirus" exact="disease" post="2019Eur. Heart J.2020412070207932391877 26.RiphagenSGomezXGonzalez-MartinezCWilkinsonNTheocharisPHyperinflammatory shock in children during COVID-19"/>
  <result pre="of myocardial injury in patients with severe coronavirus disease 2019Eur." exact="Heart" post="J.2020412070207932391877 26.RiphagenSGomezXGonzalez-MartinezCWilkinsonNTheocharisPHyperinflammatory shock in children during COVID-19 pandemicLancet20203951607160832386565 27.YinWet"/>
  <result pre="410â€&quot;448 (Lippincott Williams &amp;amp; Wilkins, 2020). 41.SandersJMMonogueMLJodlowskiTZCutrellJBPharmacologic treatments for coronavirus" exact="disease" post="2019 (COVID-19): a reviewJAMA202010.1001/jama.2020.601932282022 42.LiGDe ClercqETherapeutic options for the"/>
  <result pre="Drug Discov.20201914915032127666 43.LiSSet al.Left ventricular performance in patients with severe" exact="acute" post="respiratory syndrome: a 30-day echocardiographic follow-up studyCirculation20031081798180314504188 44.PeirisJSet al.Clinical"/>
  <result pre="Discov.20201914915032127666 43.LiSSet al.Left ventricular performance in patients with severe acute" exact="respiratory" post="syndrome: a 30-day echocardiographic follow-up studyCirculation20031081798180314504188 44.PeirisJSet al.Clinical progression"/>
  <result pre="syndrome: a 30-day echocardiographic follow-up studyCirculation20031081798180314504188 44.PeirisJSet al.Clinical progression and" exact="viral" post="load in a community outbreak of coronavirus-associated SARS pneumonia:"/>
  <result pre="coronavirus-associated SARS pneumonia: a prospective studyLancet20033611767177212781535 45.collab: The Novel Coronavirus" exact="Pneumonia" post="Emergency Response Epidemiology TeamVital surveillances: the epidemiological characteristics of"/>
  <result pre="with COVID-19 in the New York City areaJAMA202010.1001/jama.2020.677532320003 52.StefaniniGGet al.ST-elevation" exact="myocardial infarction" post="in patients with COVID-19: clinical and angiographic outcomesCirculation20201412113211632352306 53.DengQet"/>
  <result pre="Cardiology expert consensus statement on the diagnosis and treatment of" exact="adult" post="fulminant myocarditisSci. China Life Sci.20196218720230519877 55.InciardiRMet al.Cardiac involvement in"/>
  <result pre="Life Sci.20196218720230519877 55.InciardiRMet al.Cardiac involvement in a patient with coronavirus" exact="disease" post="2019 (COVID-19)JAMA Cardiol.202010.1001/jamacardio.2020.109632219357 56.HuHMaFWeiXFangYCoronavirus fulminant myocarditis saved with glucocorticoid"/>
  <result pre="a patient with coronavirus disease 2019 (COVID-19)JAMA Cardiol.202010.1001/jamacardio.2020.109632219357 56.HuHMaFWeiXFangYCoronavirus fulminant" exact="myocarditis" post="saved with glucocorticoid and human immunoglobulinEur. Heart J.202010.1093/eurheartj/ehaa19032607534 57.XuZet"/>
  <result pre="Cardiol.202010.1001/jamacardio.2020.109632219357 56.HuHMaFWeiXFangYCoronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulinEur." exact="Heart" post="J.202010.1093/eurheartj/ehaa19032607534 57.XuZet al.Pathological findings of COVID-19 associated with acute"/>
  <result pre="immunoglobulinEur. Heart J.202010.1093/eurheartj/ehaa19032607534 57.XuZet al.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir. Med.2020842042232085846 58.TavazziGet al.Myocardial localization of"/>
  <result pre="Heart J.202010.1093/eurheartj/ehaa19032607534 57.XuZet al.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir. Med.2020842042232085846 58.TavazziGet al.Myocardial localization of coronavirus"/>
  <result pre="58.TavazziGet al.Myocardial localization of coronavirus in COVID-19 cardiogenic shockEur. J." exact="Heart" post="Fail.20202291191532275347 59.WichmannDet al.Autopsy findings and venous thromboembolism in patients"/>
  <result pre="COVID-19 cardiogenic shockEur. J. Heart Fail.20202291191532275347 59.WichmannDet al.Autopsy findings and" exact="venous thromboembolism" post="in patients with COVID-19Ann. Intern. Med.202010.7326/M20-200332374815 60.SchallerTet al.Postmortem examination"/>
  <result pre="inflammation in patients with SARSEur. J. Clin. Invest.20093961862519453650 63.KwongJCet al.Acute" exact="myocardial infarction" post="after laboratory-confirmed influenza infectionN. Engl. J. Med.201837834535329365305 64.MadjidMet al.Influenza"/>
  <result pre="laboratory-confirmed influenza infectionN. Engl. J. Med.201837834535329365305 64.MadjidMet al.Influenza epidemics and" exact="acute" post="respiratory disease activity are associated with a surge in"/>
  <result pre="influenza infectionN. Engl. J. Med.201837834535329365305 64.MadjidMet al.Influenza epidemics and acute" exact="respiratory" post="disease activity are associated with a surge in autopsy-confirmed"/>
  <result pre="infectionN. Engl. J. Med.201837834535329365305 64.MadjidMet al.Influenza epidemics and acute respiratory" exact="disease" post="activity are associated with a surge in autopsy-confirmed coronary"/>
  <result pre="respiratory disease activity are associated with a surge in autopsy-confirmed" exact="coronary heart disease" post="death: results from 8 years of autopsies in 34,892"/>
  <result pre="disease activity are associated with a surge in autopsy-confirmed coronary" exact="heart" post="disease death: results from 8 years of autopsies in"/>
  <result pre="activity are associated with a surge in autopsy-confirmed coronary heart" exact="disease" post="death: results from 8 years of autopsies in 34,892"/>
  <result pre="death: results from 8 years of autopsies in 34,892 subjectsEur." exact="Heart" post="J.2007281205121017440221 65.ChongPYet al.Analysis of deaths during the severe acute"/>
  <result pre="subjectsEur. Heart J.2007281205121017440221 65.ChongPYet al.Analysis of deaths during the severe" exact="acute" post="respiratory syndrome (SARS) epidemic in Singapore: challenges in determining"/>
  <result pre="Heart J.2007281205121017440221 65.ChongPYet al.Analysis of deaths during the severe acute" exact="respiratory" post="syndrome (SARS) epidemic in Singapore: challenges in determining a"/>
  <result pre="J.2007281205121017440221 65.ChongPYet al.Analysis of deaths during the severe acute respiratory" exact="syndrome" post="(SARS) epidemic in Singapore: challenges in determining a SARS"/>
  <result pre="Engl. J. Med.20203822478248032302081 67.LibbyPTabasIFredmanGFisherEAInflammation and its resolution as determinants of" exact="acute" post="coronary syndromesCirc. Res.20141141867187924902971 68.BentzonJFOtsukaFVirmaniRFalkEMechanisms of plaque formation and ruptureCirc."/>
  <result pre="68.BentzonJFOtsukaFVirmaniRFalkEMechanisms of plaque formation and ruptureCirc. Res.20141141852186624902970 69.VargaZet al.Endothelial cell" exact="infection" post="and endotheliitis in COVID-19Lancet20203951417141832325026 70.GarciaSet al.Reduction in ST-segment elevation"/>
  <result pre="Interventional Cardiol. Engl. Ed.202010.24875/recice.M20000123 73.De RosaSet al.Reduction of hospitalizations for" exact="myocardial infarction" post="in Italy in the COVID-19 eraEur. Heart J.2020412083208832412631 74.BaldiEet"/>
  <result pre="hospitalizations for myocardial infarction in Italy in the COVID-19 eraEur." exact="Heart" post="J.2020412083208832412631 74.BaldiEet al.Out-of-hospital cardiac arrest during the COVID-19 outbreak"/>
  <result pre="in Italy in the COVID-19 eraEur. Heart J.2020412083208832412631 74.BaldiEet al.Out-of-hospital" exact="cardiac arrest" post="during the COVID-19 outbreak in ItalyN. Engl. J. Med.202010.1056/NEJMc201041832348640"/>
  <result pre="COVID-19 pandemic. A survey by the European Society of CardiologyEur." exact="Heart" post="J. Qual. Care Clin. Outcomes202010.1093/ehjqcco/qcaa04632467968 76.ChenTet al.Clinical characteristics of"/>
  <result pre="Outcomes202010.1093/ehjqcco/qcaa04632467968 76.ChenTet al.Clinical characteristics of 113 deceased patients with coronavirus" exact="disease" post="2019: retrospective studyBMJ2020368m109132217556 77.MehraMRRuschitzkaFCOVID-19 illness and heart failure: a"/>
  <result pre="deceased patients with coronavirus disease 2019: retrospective studyBMJ2020368m109132217556 77.MehraMRRuschitzkaFCOVID-19 illness" exact="and heart" post="failure: a missing link?JACC Heart Fail.2020851251432360242 78.DeweyMet al.Clinical quantitative"/>
  <result pre="patients with coronavirus disease 2019: retrospective studyBMJ2020368m109132217556 77.MehraMRRuschitzkaFCOVID-19 illness and" exact="heart" post="failure: a missing link?JACC Heart Fail.2020851251432360242 78.DeweyMet al.Clinical quantitative"/>
  <result pre="retrospective studyBMJ2020368m109132217556 77.MehraMRRuschitzkaFCOVID-19 illness and heart failure: a missing link?JACC" exact="Heart" post="Fail.2020851251432360242 78.DeweyMet al.Clinical quantitative cardiac imaging for the assessment"/>
  <result pre="Rev. Cardiol.20201742745032094693 79.MankaRet al.Myocardial edema in COVID-19 on cardiac MRIJ." exact="Heart" post="Lung Transplant.20203973073232650881 80.FriedJAet al.The variety of cardiovascular presentations of"/>
  <result pre="on cardiac MRIJ. Heart Lung Transplant.20203973073232650881 80.FriedJAet al.The variety of" exact="cardiovascular" post="presentations of COVID-19Circulation20201411930193632243205 81.PrabhuSDCytokine-induced modulation of cardiac functionCirc. Res.2004951140115315591236"/>
  <result pre="al.Guidance for cardiac electrophysiology during the COVID-19 pandemic from the" exact="Heart" post="Rhythm Society COVID-19 task force; electrophysiology section of the"/>
  <result pre="Heart Rhythm Society COVID-19 task force; electrophysiology section of the" exact="American" post="College of Cardiology; and the electrocardiography and arrhythmias committee"/>
  <result pre="electrocardiography and arrhythmias committee of the council on clinical cardiology," exact="American" post="Heart AssociationCirculation2020141e823e83132228309 84.PanigadaMet al.Hypercoagulability of COVID-19 patients in intensive"/>
  <result pre="and arrhythmias committee of the council on clinical cardiology, American" exact="Heart" post="AssociationCirculation2020141e823e83132228309 84.PanigadaMet al.Hypercoagulability of COVID-19 patients in intensive care"/>
  <result pre="Thromb. Haemost.2020181738174232302438 85.RanucciMet al.The procoagulant pattern of patients with COVID-19" exact="acute" post="respiratory distress syndromeJ. Thromb. Haemost.2020181747175132302448 86.TaylorFBJr.et al.Towards definition, clinical"/>
  <result pre="Haemost.2020181738174232302438 85.RanucciMet al.The procoagulant pattern of patients with COVID-19 acute" exact="respiratory" post="distress syndromeJ. Thromb. Haemost.2020181747175132302448 86.TaylorFBJr.et al.Towards definition, clinical and"/>
  <result pre="a scoring system for disseminated intravascular coagulationThromb. Haemost.2001861327133011816725 87.OxleyTJet al.Large-vessel" exact="stroke" post="as a presenting feature of COVID-19 in the youngN."/>
  <result pre="of COVID-19 in the youngN. Engl. J. Med.2020382e6032343504 88.BellostaRet al.Acute" exact="limb ischemia" post="in patients with COVID-19 pneumoniaJ. Vasc. Surg.202010.1016/j.jvs.2020.04.48332360679 89.ParanjpeIet al.Association"/>
  <result pre="COVID-19 in the youngN. Engl. J. Med.2020382e6032343504 88.BellostaRet al.Acute limb" exact="ischemia" post="in patients with COVID-19 pneumoniaJ. Vasc. Surg.202010.1016/j.jvs.2020.04.48332360679 89.ParanjpeIet al.Association"/>
  <result pre="al.Anticoagulant treatment is associated with decreased mortality in severe coronavirus" exact="disease" post="2019 patients with coagulopathyJ. Thromb. Haemost.2020181094109932220112 91.QiuHet al.Clinical and"/>
  <result pre="91.QiuHet al.Clinical and epidemiological features of 36 children with coronavirus" exact="disease" post="2019 (COVID-19) in Zhejiang, China: an observational cohort studyLancet"/>
  <result pre="cohort studyLancet Infect. Dis.20202068969632220650 92.VerdoniLet al.An outbreak of severe Kawasaki-like" exact="disease" post="at the Italian epicentre of the SARS-CoV-2 epidemic: an"/>
  <result pre="observational cohort studyLancet20203951771177832410760 93.AslamSMehraMRCOVID-19: yet another coronavirus challenge in transplantationJ." exact="Heart" post="Lung Transplant.20203940840932253113 94.LiFCaiJDongNFirst cases of COVID-19 in heart transplantation"/>
  <result pre="in transplantationJ. Heart Lung Transplant.20203940840932253113 94.LiFCaiJDongNFirst cases of COVID-19 in" exact="heart" post="transplantation from ChinaJ. Heart Lung Transplant.20203949649732362394 95.KetchamSWet al.Coronavirus disease-2019"/>
  <result pre="Transplant.20203940840932253113 94.LiFCaiJDongNFirst cases of COVID-19 in heart transplantation from ChinaJ." exact="Heart" post="Lung Transplant.20203949649732362394 95.KetchamSWet al.Coronavirus disease-2019 in heart transplant recipients"/>
  <result pre="transplantation from ChinaJ. Heart Lung Transplant.20203949649732362394 95.KetchamSWet al.Coronavirus disease-2019 in" exact="heart" post="transplant recipients in southeastern Michigan: a case seriesJ. Card."/>
  <result pre="seriesJ. Card. Fail.20202645746132417380 96.LatifFet al.Characteristics and outcomes of recipients of" exact="heart" post="transplant with coronavirus disease 2019JAMA Cardiol.202010.1001/jamacardio.2020.215932402056 97.GosainRet al.COVID-19 and"/>
  <result pre="al.Characteristics and outcomes of recipients of heart transplant with coronavirus" exact="disease" post="2019JAMA Cardiol.202010.1001/jamacardio.2020.215932402056 97.GosainRet al.COVID-19 and cancer: a comprehensive reviewCurr."/>
  <result pre="and cancer: a comprehensive reviewCurr. Oncol. Rep.2020225332385672 98.GanatraSHammondSPNohriaAThe novel coronavirus" exact="disease" post="(COVID-19) threat for patients with cardiovascular disease and cancerJACC"/>
  <result pre="Rep.2020225332385672 98.GanatraSHammondSPNohriaAThe novel coronavirus disease (COVID-19) threat for patients with" exact="cardiovascular disease" post="and cancerJACC CardioOncol.202010.1016/j.jaccao.2020.03.00132292919 99.LiangWet al.Cancer patients in SARS-CoV-2 infection:"/>
  <result pre="98.GanatraSHammondSPNohriaAThe novel coronavirus disease (COVID-19) threat for patients with cardiovascular" exact="disease" post="and cancerJACC CardioOncol.202010.1016/j.jaccao.2020.03.00132292919 99.LiangWet al.Cancer patients in SARS-CoV-2 infection:"/>
  <result pre="100.TurnerAJHiscoxJAHooperNMACE2: from vasopeptidase to SARS virus receptorTrends Pharmacol. Sci.20042529129415165741 101.GTEx" exact="Portal" post="(ACE2). Gene expression for ACE2https://www.gtexportal.org/home/gene/ACE2 (2020). 102.ChenLLiXChenMFengYXiongCThe ACE2 expression"/>
  <result pre="Gene expression for ACE2https://www.gtexportal.org/home/gene/ACE2 (2020). 102.ChenLLiXChenMFengYXiongCThe ACE2 expression in human" exact="heart" post="indicates new potential mechanism of heart injury among patients"/>
  <result pre="ACE2 expression in human heart indicates new potential mechanism of" exact="heart" post="injury among patients infected with SARS-CoV-2Cardiovasc. Res.20201161097110032227090 103.Litvinukova, M."/>
  <result pre="M. et al. Cells and gene expression programs in the" exact="adult" post="human heart. Preprint at bioRxiv10.1101/2020.04.03.024075 (2020). 104.Kaiser, J. How"/>
  <result pre="Genet.28, 715â€&quot;718 (2020). 106.ImaiYet al.Angiotensin-converting enzyme 2 protects from severe" exact="acute" post="lung failureNature200543611211616001071 107.KubaKet al.A crucial role of angiotensin converting"/>
  <result pre="Med.20051187587916007097 108.CrackowerMAet al.Angiotensin-converting enzyme 2 is an essential regulator of" exact="heart" post="functionNature200241782282812075344 109.ThomasMCet al.Genetic Ace2 deficiency accentuates vascular inflammation and"/>
  <result pre="is an essential regulator of heart functionNature200241782282812075344 109.ThomasMCet al.Genetic Ace2" exact="deficiency" post="accentuates vascular inflammation and atherosclerosis in the ApoE knockout"/>
  <result pre="essential regulator of heart functionNature200241782282812075344 109.ThomasMCet al.Genetic Ace2 deficiency accentuates" exact="vascular" post="inflammation and atherosclerosis in the ApoE knockout mouseCirc. Res.201010788889720671240"/>
  <result pre="heart functionNature200241782282812075344 109.ThomasMCet al.Genetic Ace2 deficiency accentuates vascular inflammation and" exact="atherosclerosis" post="in the ApoE knockout mouseCirc. Res.201010788889720671240 110.Zhao, Y. et"/>
  <result pre="Commun.202052613514032199615 112.SungnakWet al.SARS-CoV-2 entry factors are highly expressed in nasal" exact="epithelial" post="cells together with innate immune genesNat. Med.20202668168732327758 113.VaduganathanMet al.Reninâ€&quot;angiotensinâ€&quot;aldosterone"/>
  <result pre="patients with COVID-19N. Engl. J. Med.20203821653165932227760 114.MonteilVet al.Inhibition of SARS-CoV-2" exact="infections" post="in engineered human tissues using clinical-grade soluble human ACE2Cell202018190591332333836"/>
  <result pre="pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in" exact="acute" post="respiratory distress syndromeCrit. Care20172123428877748 117.WadmanMCouzin-FrankelJKaiserJMatacicCA rampage through the bodyScience202036835636032327580"/>
  <result pre="clinical trial of recombinant human angiotensin-converting enzyme 2 in acute" exact="respiratory" post="distress syndromeCrit. Care20172123428877748 117.WadmanMCouzin-FrankelJKaiserJMatacicCA rampage through the bodyScience202036835636032327580 118.PuellesVGet"/>
  <result pre="of the reninâ€&quot;angiotensin system be withdrawn in patients with COVID-19?Eur." exact="Heart" post="J.2020411801180332196087 120.SommersteinRKochenMMMesserliFHGraniCCoronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin"/>
  <result pre="system be withdrawn in patients with COVID-19?Eur. Heart J.2020411801180332196087 120.SommersteinRKochenMMMesserliFHGraniCCoronavirus" exact="disease" post="2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have"/>
  <result pre="2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a" exact="biphasic" post="effect?J. Am. Heart Assoc.20209e01650932233753 121.FerrarioCMet al.Effect of angiotensin-converting enzyme"/>
  <result pre="angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect?J. Am." exact="Heart" post="Assoc.20209e01650932233753 121.FerrarioCMet al.Effect of angiotensin-converting enzyme inhibition and angiotensin"/>
  <result pre="addresses concerns re: using RAAS antagonists in COVID-19. AHA Professional" exact="Heart" post="Dailyhttps://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHA-statement-addresses-concerns-re-using-RAAS-antagonists-in-COVID-19.jsp (2020). 123.de Simone, G. Position statement of the"/>
  <result pre="123.de Simone, G. Position statement of the ESC council on" exact="hypertension" post="on ACE-inhibitors and angiotensin receptor blockers. ESC escardiohttps://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang (2020)."/>
  <result pre="Cardiology.Scientific statement on using reninâ€&quot;angiotensin system blockers in patients with" exact="cardiovascular disease" post="and COVID-19Chin. J. Cardiol.202048E014 125.de AbajoFJet al.Use of reninâ€&quot;angiotensinâ€&quot;aldosterone"/>
  <result pre="statement on using reninâ€&quot;angiotensin system blockers in patients with cardiovascular" exact="disease" post="and COVID-19Chin. J. Cardiol.202048E014 125.de AbajoFJet al.Use of reninâ€&quot;angiotensinâ€&quot;aldosterone"/>
  <result pre="and angiotensin II receptor blockers with testing positive for coronavirus" exact="disease" post="2019 (COVID-19)JAMA Cardiol.202010.1001/jamacardio.2020.185532432651 129.IshiyamaYet al.Upregulation of angiotensin-converting enzyme 2"/>
  <result pre="2019 (COVID-19)JAMA Cardiol.202010.1001/jamacardio.2020.185532432651 129.IshiyamaYet al.Upregulation of angiotensin-converting enzyme 2 after" exact="myocardial infarction" post="by blockade of angiotensin II receptorsHypertension20044397097615007027 130.SolerMJet al.Localization of"/>
  <result pre="of ACE2 in the renal vasculature: amplification by angiotensin II" exact="type 1" post="receptor blockade using telmisartanAm. J. Physiol. Ren. Physiol2009296F398F405 131.BurrellLMet"/>
  <result pre="131.BurrellLMet al.Myocardial infarction increases ACE2 expression in rat and humansEur." exact="Heart" post="J.20052636937515671045 132.OcaranzaMPet al.Enalapril attenuates downregulation of angiotensin-converting enzyme 2"/>
  <result pre="downregulation of angiotensin-converting enzyme 2 in the late phase of" exact="ventricular dysfunction" post="in myocardial infarcted ratHypertension20064857257816908757 133.LuqueMet al.Effects of captopril related"/>
  <result pre="blockerAm. J. Hypertens.201528152124842388 135.EpelmanSet al.Soluble angiotensin-converting enzyme 2 in human" exact="heart" post="failure: relation with myocardial function and clinical outcomesJ. Card."/>
  <result pre="Card. Fail.20091556557119700132 136.RamchandJet al.Plasma ACE2 activity predicts mortality in aortic" exact="stenosis" post="and is associated with severe myocardial fibrosisJACC Cardiovasc. Imaging20201365566431607667"/>
  <result pre="increased plasma angiotensin converting enzyme 2 activity is associated with" exact="atrial fibrillation" post="and more advanced left atrial structural remodellingEuropace2017191280128727738071 138.RamchandJPatelSKSrivastavaPMFarouqueOBurrellLMElevated plasma"/>
  <result pre="plasma angiotensin converting enzyme 2 activity is associated with atrial" exact="fibrillation" post="and more advanced left atrial structural remodellingEuropace2017191280128727738071 138.RamchandJPatelSKSrivastavaPMFarouqueOBurrellLMElevated plasma"/>
  <result pre="novel coronavirus (2019-nCoV) in vitroCell Res.20203026927132020029 146.SavarinoABoelaertJRCassoneAMajoriGCaudaREffects of chloroquine on" exact="viral" post="infections: an old drug against todayâ€™s diseases?Lancet Infect. Dis.2003372272714592603"/>
  <result pre="an old drug against todayâ€™s diseases?Lancet Infect. Dis.2003372272714592603 147.ISAC/Elsevier statement." exact="Joint" post="ISAC and Elsevier statement on Gautret et al. paper."/>
  <result pre="needed on the use of chloroquine and hydroxychloroquine for coronavirus" exact="disease" post="2019JAMA Netw. Open.20203e20903532330276 151.MercuroNJet al.Risk of QT interval prolongation"/>
  <result pre="without concomitant azithromycin among hospitalized patients testing positive for coronavirus" exact="disease" post="2019 (COVID-19)JAMA Cardiol.202010.1001/jamacardio.2020.183432356863 152.HancoxJCHasnainMViewegWVCrouseELBaranchukAAzithromycin, cardiovascular risks, QTc interval prolongation,"/>
  <result pre="patients testing positive for coronavirus disease 2019 (COVID-19)JAMA Cardiol.202010.1001/jamacardio.2020.183432356863 152.HancoxJCHasnainMViewegWVCrouseELBaranchukAAzithromycin," exact="cardiovascular" post="risks, QTc interval prolongation, Torsade de Pointes, and regulatory"/>
  <result pre="Med.20203821787179932187464 160.StockmanLJBellamyRGarnerPSARS: systematic review of treatment effectsPLoS Med.20063e34316968120 161.Centers for" exact="Disease" post="Control and Prevention. Interim laboratory biosafety guidelines for handling"/>
  <result pre="biosafety guidelines for handling and processing specimens associated with coronavirus" exact="disease" post="2019 (COVID-19).https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html (CDC, 2020). 162.World Health Organization. Laboratory biosafety"/>
  <result pre="2020). 162.World Health Organization. Laboratory biosafety guidance related to coronavirus" exact="disease" post="2019 (COVID-19). https://www.who.int/publications-detail/laboratory-biosafety-guidance-related-to-coronavirus-disease-2019-(covid-19) (2020). 163.BaoLet al.The pathogenicity of SARS-CoV-2"/>
  <result pre="dogs, and other domesticated animals to SARS-coronavirus 2Science20203681016102032269068 166.McCrayPBJr.et al.Lethal" exact="infection" post="of K18-hACE2 mice infected with severe acute respiratory syndrome"/>
  <result pre="2Science20203681016102032269068 166.McCrayPBJr.et al.Lethal infection of K18-hACE2 mice infected with severe" exact="acute" post="respiratory syndrome coronavirusJ. Virol.20078181382117079315 167.KimYIet al.Infection and rapid transmission"/>
  <result pre="166.McCrayPBJr.et al.Lethal infection of K18-hACE2 mice infected with severe acute" exact="respiratory" post="syndrome coronavirusJ. Virol.20078181382117079315 167.KimYIet al.Infection and rapid transmission of"/>
  <result pre="al.Lethal infection of K18-hACE2 mice infected with severe acute respiratory" exact="syndrome" post="coronavirusJ. Virol.20078181382117079315 167.KimYIet al.Infection and rapid transmission of SARS-CoV-2"/>
  <result pre="Host Microbe.20202770470932259477 168.ParkSJet al.Ferret animal model of severe fever with" exact="thrombocytopenia" post="syndrome phlebovirus for human lethal infection and pathogenesisNat. Microbiol.2019443844630531978"/>
  <result pre="Microbe.20202770470932259477 168.ParkSJet al.Ferret animal model of severe fever with thrombocytopenia" exact="syndrome" post="phlebovirus for human lethal infection and pathogenesisNat. Microbiol.2019443844630531978 169.ChanJFet"/>
  <result pre="of severe fever with thrombocytopenia syndrome phlebovirus for human lethal" exact="infection" post="and pathogenesisNat. Microbiol.2019443844630531978 169.ChanJFet al.Simulation of the clinical and"/>
  <result pre="169.ChanJFet al.Simulation of the clinical and pathological manifestations of coronavirus" exact="disease" post="2019 (COVID-19) in golden Syrian hamster model: implications for"/>
  <result pre="disease 2019 (COVID-19) in golden Syrian hamster model: implications for" exact="disease" post="pathogenesis and transmissibilityClin. Infect. Dis.202010.1093/cid/ciaa32532667973 170.Bao, L. et al."/>
  <result pre="Preprint at bioRxiv10.1101/2020.03.13.990226 (2020). 171.ChenIYMatsaEWuJCInduced pluripotent stem cells: at the" exact="heart" post="of cardiovascular precision medicineNat. Rev. Cardiol.20161333334927009425 172.ShiYInoueHWuJCYamanakaSInduced pluripotent stem"/>
  <result pre="bioRxiv10.1101/2020.03.13.990226 (2020). 171.ChenIYMatsaEWuJCInduced pluripotent stem cells: at the heart of" exact="cardiovascular" post="precision medicineNat. Rev. Cardiol.20161333334927009425 172.ShiYInoueHWuJCYamanakaSInduced pluripotent stem cell technology:"/>
 </snippets>
</snippetsTree>
